{"Title": ["Biotech Stocks Facing FDA Decision In July 2020", "3 Reasons Jazz Pharmaceuticals Is A Hot Buy Right Now", "FDA Nod For JAZZ's Drug, BYSI's PROTECTIVE-2 Trial Meets Goals, EDSA To Begin COVID-19 Drug Trial", "BUZZ-U.S. STOCKS ON THE MOVE-Boeing, Chesapeake Energy, Ideanomics", "2 Top Healthcare Stocks to Buy Right Now", "Sum Up The Pieces: VV Could Be Worth $150", "Why Jazz Pharmaceuticals' Symphony of Growth Is About to End", "Jazz Pharmaceuticals (JAZZ) Q1 2020 Earnings Call Transcript", "Biotech Stocks Facing FDA Decision In July 2020", "2 Cheap Healthcare Stocks to Buy Now", "Can This Small-Cap Biotech Win a $1 Billion Market Opportunity for Narcolepsy?", "Why Avadel Pharmaceuticals Stock Is Crushing It Today", "Validea's Top Five Healthcare Stocks Based On Peter Lynch - 4/19/2020", "Analysts Anticipate VV Will Reach $151", "GILD Seeks To Revoke Coveted Status, ELOX Pauses Trial, PRQR On Watch", "5 Healthcare Stocks That Haven't Been This Cheap in at Least 10 Years", "Why Jazz Pharmaceuticals Sang Off-Key in Q1", "Jazz Pharmaceuticals is Now Oversold (JAZZ)", "Got $5,000? Here Are 4 Stocks the Smartest Investors Are Buying Right Now", "1 Cheap Biotech Stock to Buy", "Validea's Top Five Healthcare Stocks Based On Peter Lynch - 3/15/2020", "Look Under The Hood: VOT Has 18% Upside", "The 11 Best (And 11 Worst) Stocks of the 11-Year Bull Market", "6 Quality Biotech Stocks on Sale Now", "Validea Benjamin Graham Strategy Daily Upgrade Report - 3/24/2020", "Jazz Pharmaceuticals (JAZZ) Q4 2019 Earnings Call Transcript", "Oversold Conditions For Jazz Pharmaceuticals (JAZZ)", "Here's Why Avadel Pharmaceuticals Stock Jumped Higher Today", "Validea Joel Greenblatt Strategy Daily Upgrade Report - 2/21/2020", "JAZZ Makes Notable Cross Below Critical Moving Average", "BBI Awaits Data In Q2, BLPH Breathes Easy, Big Day For BXRX Tomorrow", "Jazz Pharma: FDA Grants Priority Review For Lurbinectedin", "Stock Alert: Will JAZZ's Downbeat Outlook Pull Down The Stock?", "Could This Cancer Drug Developer\u2019s Stock Make You Rich?", "Could This Cancer Drug Developer\u2019s Stock Make You Rich?", "3 Top Value Stocks You'll Want to Own in February", "First Week of JAZZ September 18th Options Trading", "Validea's Top Five Healthcare Stocks Based On Peter Lynch - 1/19/2020", "2 Stocks That Are Absurdly Cheap Right Now", "Interesting JAZZ Put And Call Options For February 21st", "Validea's Top Five Healthcare Stocks Based On Peter Lynch - 2/16/2020", "Analysts Forecast 11% Gains Ahead For The Holdings of PPH", "PharmaMar And Jazz Pharma Sign License Deal For Lurbinectedin In U.S.", "3 Top Healthcare Stocks to Buy Right Now", "Up 25% in 2 Months, This Healthcare Stock Could Climb Even Higher", "Validea's Top Five Healthcare Stocks Based On Peter Lynch - 12/15/2019", "How The Pieces Add Up: PJP Targets $70", "Why Has Jazz Pharma's Stock Rallied Nearly 20% In A Month?", "The 10 Best Healthcare Stocks of the Decade", "Analysts Forecast 11% Gains Ahead For The Holdings of PPH", "PharmaMar And Jazz Pharma Sign License Deal For Lurbinectedin In U.S.", "Validea Joel Greenblatt Strategy Daily Upgrade Report - 10/8/2019", "Sum Up The Parts: FNX Could Be Worth $76", "Jazz Pharma Presents JZP-258 Phase 3 Study Data At World Sleep 2019", "5 GARP Stocks To Buy Today", "Why Has Jazz Pharma's Stock Rallied Nearly 20% In A Month?", "JAZZ Crosses Above Key Moving Average Level", "Jazz Pharmaceuticals Sings a Sweet Tune in Q2", "Jazz Pharmaceuticals (JAZZ) Q2 2019 Earnings Call Transcript", "The Implied Analyst 12-Month Target For OSIZ", "3 Incredibly Cheap Healthcare Stocks", "Interesting JAZZ Put And Call Options For August 16th", "Analysts Expect SCIU Will Reach $36", "What's Next for Sarepta Therapeutics After Its Surprising FDA Rejection", "JAZZ Crosses Above Key Moving Average Level", "Jazz Pharmaceuticals Sings a Sweet Tune in Q2", "Jazz Pharmaceuticals (JAZZ) Q2 2019 Earnings Call Transcript", "First Week of JAZZ May 17th Options Trading", "Is Jazz Pharmaceuticals (JAZZ) a Good Value Investor Pick?", "The Zacks Analyst Blog Highlights: Jazz Pharmaceuticals, Lululemon Athletica, ABIOMED and DexCom", "Health Care Sector Update for 05/08/2019: BHVN,GHDX,JAZZ,PTLA", "Health Care Sector Update for 05/08/2019: GHDX,JAZZ,PLTA", "The Stock Market Has Done This 37 Times Since 1950", "Jazz Pharmaceuticals (JAZZ) Surges: Stock Moves 7.9% Higher", "Jazz Pharma (JAZZ) Q4 Earnings & Sales Beat, Stock Up 8%", "Jazz Pharmaceuticals PLC (JAZZ) Q4 2018 Earnings Conference Call Transcript", "Earnings Reaction History: JAZZ PHARMACEUT, 50.0% Follow-Through Indicator, 4.6% Sensitive", "After-Hours Earnings Report for February 26, 2019 : EOG, PSA, PANW, MELI, MYL, VEEV, CSGP, JAZZ, MASI, TOL, CW, PEN", "The 10 Top Stocks of the 10-Year Bull Market", "Factors to Know Ahead of Herbalife's (HLF) Q4 Earnings", "Health Care Sector Update for 02/12/2019: JAZZ,GILD,KMDA,OHI", "Why Jazz (JAZZ) Could Beat Earnings Estimates Again", "First Week of JAZZ September 20th Options Trading", "5 Biotech Stocks That Could Face M&A Next!", "3 Bargain Stocks You Can Buy Right Now", "Jazz Inks Deal with Codiak to Develop Exosome Therapeutics", "Mylan (MYL) to Report Q4 Earnings: What's in the Offing?", "Factors to Know Ahead of Herbalife's (HLF) Q4 Earnings", "Health Care Sector Update for 02/12/2019: JAZZ,GILD,KMDA,OHI", "Why Jazz (JAZZ) Could Beat Earnings Estimates Again", "Surprising Analyst 12-Month Target For VLUE", "Jazz (JAZZ) Increases Share Buyback Authorization by $400M", "Why Is Jazz (JAZZ) Up 3% Since Last Earnings Report?", "3 of the Cheapest Drug Stocks You Can Buy in 2019", "Analysts Forecast 21% Upside For JKH", "Moving Average Crossover Alert: Jazz Pharmaceuticals (JAZZ)", "Health Care Sector Update for 11/09/2018: JAZZ,ACRX,ACET,NTRA", "Jazz Pharma (JAZZ) Beats on Q3 Earnings, Lowers Sales View", "Why Jazz Pharmaceuticals plc Stock Is Slumping Today", "Jazz Pharmaceuticals (JAZZ) Tops Q3 Earnings Estimates", "Earnings Reaction History: Jazz Pharmaceuticals, Inc., 33.3% Follow-Through Indicator, 3.2% Sensitive", "Health Care Sector Update for 11/29/2018: ALKS,EYPT,JAZZ", "Bullish Two Hundred Day Moving Average Cross - JAZZ", "First Week of JAZZ November 16th Options Trading", "5 Low Price-to-Book Stocks to Buy in a Volatile Market", "JAZZ Crosses Below Key Moving Average Level", "JAZZ or ZTS: Which Is the Better Value Stock Right Now?", "Is Jazz Pharmaceuticals a Great Stock for Value Investors?", "Jazz Pharmaceuticals is Now Oversold (JAZZ)", "After-Hours Earnings Report for November 6, 2018 : PXD, DXC, PAA, DVN, GDDY, JKHY, FANG, DXCM, LNT, JAZZ, XEC, KAR", "Bullish Two Hundred Day Moving Average Cross - JAZZ", "First Week of JAZZ November 16th Options Trading", "5 Low Price-to-Book Stocks to Buy in a Volatile Market", "5 Low-Cost Biotech Stocks With High Levels of Growth", "8 Undervalued Biotech Stocks to Watch", "Analysts See 10% Upside For SCIU", "Jazz Pharma's (JAZZ) Stock Down Despite Q2 Earnings Beat", "3 Biotech Stocks Analysts Say Are Market Winners", "Why Is Jazz (JAZZ) Down 2.4% Since Last Earnings Report?", "JAZZ December 2019 Options Begin Trading", "Jazz's (JAZZ) Leukemia Drug Vyxeos Gets Approval in Europe", "5 Low-Cost Biotech Stocks With High Levels of Growth", "8 Undervalued Biotech Stocks to Watch", "Zillow Group (ZG) to Report Q2 Earnings: Is a Beat in Store?", "ANSYS (ANSS) to Report Q2 Earnings: What's in the Offing?", "7 Biotech Stocks With Big Upcoming Catalysts", "Noteworthy Tuesday Option Activity: JAZZ, CAR, AXDX", "After-Hours Earnings Report for August 7, 2018 : DIS, PXD, DXC, CLR, PAA, HST, SNAP, JAZZ, IFF, ALB, XEC, PE", "Jazz Pharma (JAZZ) Q2 Earnings Coming Up: What's in Store?", "5 Low Price-to-Book Stocks Worth Buying in July", "5 Low Price-to-Book Stocks Worth Buying in July", "Aclaris Stock Up on JAK Inhibitor's Encouraging Activity", "Dermira (DERM) Gains 5% in a Week, Post-Qbrexa Approval", "What's in Store for Catalyst (CPRX) This Earnings Season?", "Aerie (AERI) to Report Q2 Earnings: What's in the Offing?", "5 Stocks Near 52-Week High: Is More Upside in the Cards?", "Jazz Pharmaceuticals' sNDA for Xyrem Gets Priority Review", "5 Low-Beta Stocks to Buy as Trade Conflict Intensifies", "Small Drugmakers Edging Out the Bigshots: 7 Stocks to Buy", "Zacks.com highlights: Jazz Pharmaceuticals, Baxter International, Boise Cascade, Insight Enterprises and Comfort Systems USA", "5 Stocks Near 52-Week High With More Room to Run", "10 Underappreciated Biotech Stocks to Buy", "Jazz Sells Pain Drug Prialt's Rights to TerSera Therapeutics", "5 Stocks Near 52-Week High: Is More Upside in the Cards?", "Jazz Pharmaceuticals' sNDA for Xyrem Gets Priority Review", "5 Low-Beta Stocks to Buy as Trade Conflict Intensifies", "Small Drugmakers Edging Out the Bigshots: 7 Stocks to Buy", "Zacks.com highlights: Jazz Pharmaceuticals, Baxter International, Boise Cascade, Insight Enterprises and Comfort Systems USA", "5 Stocks Near 52-Week High With More Room to Run", "10 Underappreciated Biotech Stocks to Buy", "Jazz Pharmaceuticals (JAZZ) Up 16.9% Since Earnings Report: Can It Continue?", "3 Biotechs on the FDA's Naughty List That Should Be on Investors' Buy Lists", "Look Under The Hood: QUS Has 10% Upside", "Jazz Pharmaceuticals (JAZZ) Q1 Earnings, Sales Top Estimates", "3 Top Biotech Stocks to Buy in May", "Earnings Reaction History: Jazz Pharmaceuticals, Inc., 28.6% Follow-Through Indicator, 3.1% Sensitive", "Jazz Pharmaceuticals (JAZZ) Q4 Earnings: What to Expect?", "Jazz Pharmaceuticals (JAZZ) Q1 Earnings: What's in Store?", "SIZE's Underlying Holdings Could Mean 12% Gain Potential", "First Week of May 18th Options Trading For Jazz Pharmaceuticals (JAZZ)", "Should Value Investors Pick Jazz Pharmaceuticals (JAZZ) Stock?", "Jazz Pharmaceuticals (JAZZ) Shares Cross Above 200 DMA", "Jazz Pharmaceuticals (JAZZ) Q4 Earnings Miss, Sales Up Y/Y", "After-Hours Earnings Report for February 27, 2018 : EOG, ESRX, WDAY, SQ, ALB, FMX, LYV, JAZZ, MIDD, VEEV, BWXT, BIO", "Jazz Pharmaceuticals (JAZZ) Q4 Earnings: What to Expect?", "Jazz Pharmaceuticals (JAZZ) Q1 Earnings: What's in Store?", "Implied DWPP Analyst Target Price: $32", "Notable ETF Outflow Detected - IHE, PFE, PRGO, JAZZ", "Concert Pharmaceuticals Plunges on Patent Petition Setback", "5 Biotech Stocks That Could Be Bought Out in 2018", "ImmunoGen Starts Phase I Study on Leukemia Candidate IMGN632", "Jazz Submits NDA to FDA for JZP-110 to Cure Sleep Disorder", "Health Care Sector Update for 12/21/2017: JAZZ,AEZS,JNJ,ACST,ACST.V", "Why ImmunoGen Jumped Higher Today", "Health Care Sector Update for 12/19/2017: CGIX,TMO,PFNX,JAZZ,THC", "ImmunoGen, Inc. Moves Forward", "Jazz Pharmaceuticals (JAZZ) Q3 Earnings Top, 2017 View Cut", "After-Hours Earnings Report for November 7, 2017 : MAR, ETP, ETE, CLR, AGU, ALNY, XEC, TTWO, DVA, JKHY, JAZZ, PPC", "Asymmetry Capital Management, L.P. Buys Insmed Inc, Ionis Pharmaceuticals Inc, HMS Holdings ...", "Is ImmunoGen Running Out of Steam, or Taking a Breather?", "Jazz Pharmaceuticals Enters Oversold Territory (JAZZ)", "ImmunoGen to Push Leukemia Candidate into Phase I Trial", "Notable Two Hundred Day Moving Average Cross - JAZZ", "Genocea Biosciences (GNCA) Jumps: Stock Rises 24.8%", "Rigel Pharmaceuticals (RIGL) in Focus: Stock Moves 12.1% Higher", "Synergy Pharmaceuticals (SGYP) Surges: Stock Moves 12.1% Higher", "ImmunoGen (IMGN) in Focus: Stock Moves 17.3% Higher", "5 Excellent Value Stocks Based on Low PEG Ratio", "3 Pharma/Biotech Sector Bargains for a Healthy Portfolio", "5 Key Things You Should Watch With Jazz Pharmaceuticals", "Jazz Pharmaceuticals, O'Reilly Automotive and Tesla highlighted as Zacks Bull and Bear of the Day", "Bull of the Day: Jazz Pharmaceuticals (JAZZ)", "Zacks.com featured highlights include Lantheus Holdings, Jazz Pharmaceuticals, Gray Television, Aetna and Uniti Group", "Immunogen Inks Deal With Jazz Pharma to Develop ADC Molecule", "ImmunoGen (IMGN) in Focus: Stock Moves 17.3% Higher", "5 Excellent Value Stocks Based on Low PEG Ratio", "3 Pharma/Biotech Sector Bargains for a Healthy Portfolio", "Midday Update: Wall Street Recovers From Overnight Sell-Off as Supports Remain Intact", "U.S. Stock Futures Roiled By North Korean Missile Test Over Japan", "Health Care Sector Update for 08/29/2017: JNJ, PFE, ABT, MRK, AMGN, IMGN, ETRM", "Why Movado Group, Catalent, and ImmunoGen Jumped Today", "Health Care Sector Update for 08/29/2017: IMGN,JAZZ,JUNO,ACOR", "Why ImmunoGen, Inc. Jumped Higher Today", "Enanta Pharmaceuticals (ENTA) Looks Good: Stock Adds 9.6% in Session", "Analysts Expect 11% Upside For The Holdings of IYH", "Ironwood Pharma's Combination Gout Drug Gets FDA Approval", "Rally Set to Resume: Buy These 5 Value Picks on the Dip", "Jazz Pharmaceuticals Arm Announces $500M Senior Notes Offer", "Endo International (ENDP) Jumps: Stock Rises 6.9%", "Jounce Therapeutics (JNCE) Jumps: Stock Moves 7.4% Higher", "RK Capital Management, LLC Buys Electronics for Imaging Inc, Douglas Dynamics Inc, KBR Inc, ...", "The 3 Top Stocks for Your IRA in August", "Oversold Conditions For Jazz Pharmaceuticals (JAZZ)", "Jazz Pharma (JAZZ) Q2 Earnings & Revenues Miss, View Intact", "After-Hours Earnings Report for August 8, 2017 : DIS, PCLN, MNST, ETP, ETE, FNV, CLR, ANDV, IFF, JAZZ, XEC, CLNS", "Can Jazz Pharma (JAZZ) Spring a Surprise in Q2 Earnings?", "Sum Up The Pieces: PPH Could Be Worth $65", "AVEO's Kidney Cancer Candidate Gets CHMP Recommendation", "3 Reasons Jazz Pharmaceuticals Stock Could Fall", "3 Mid-Cap Stocks With Big-Cap Potential", "Jazz Pharmaceuticals (JAZZ) Misses Q1 Earnings & Sales", "Earnings Reaction History: Jazz Pharmaceuticals, Inc., 25.0% Follow-Through Indicator, 2.9% Sensitive", "After-Hours Earnings Report for May 9, 2017 : DIS, PCLN, NVDA, EA, SLF, MCHP, FNV, REG, JAZZ, DOX, ZAYO, TSRO", "Jazz Pharma (JAZZ) Q1 Earnings: Stock Likely to Disappoint?", "3 Top Biotech Stocks to Buy Now", "Analysts Predict 11% Gains Ahead For The Holdings of IYH", "SPDR S&P Pharmaceuticals ETF Experiences Big Outflow", "4 of the Cheapest Biotech Stocks in the World", "Jazz Pharmaceuticals (JAZZ) Misses Q1 Earnings & Sales", "Health Care Sector Update for 04/06/2017: JAZZ,AKTX,NVGN", "Bridges Investment Management Inc Buys iShares Core S&P Small-Cap, Vanguard FTSE All World ...", "Jazz Pharma Completes NDA Filing for Leukemia Drug to FDA", "Jazz Pharma (JAZZ) Up 7.6% Since Earnings Report: Can It Continue?", "Why You're Smart to Buy Jazz Pharmaceuticals plc", "Should You Drop What You're Doing and Buy Jazz Pharmaceuticals Stock?", "Monday's ETF with Unusual Volume: URTH", "Jazz Initiates Phase III Study for Narcolepsy Candidate", "Jazz Pharma (JAZZ) Q4 Earnings Beat, Sales Miss Estimates", "After-Hours Earnings Report for February 28, 2017 : CRM, ROST, PANW, UHS, TSRO, JAZZ, AR, DXCM, EPR, LOGM, ACAD, BUFF", "Earnings Reaction History: Jazz Pharmaceuticals, Inc., 22.2% Follow-Through Indicator, 2.9% Sensitive", "Noteworthy ETF Outflows: IHE, MYL, JAZZ, PRGO", "Jazz Pharma (JAZZ) Q4 Earnings: Is a Surprise in Store?", "Jazz Sleep Disorder Drug Positive in Phase III Studies", "Bullish Two Hundred Day Moving Average Cross - JAZZ", "5 Drug Stocks Poised to Beat Earnings Estimates in Q4", "Why Jazz Pharmaceuticals PLC's Shareholders Didn't Sleep on This 12% Gain in January", "These 3 Biotech Stocks Are Ridiculously Cheap", "Top Healthcare Stocks to Buy in 2017", "XPH, JAZZ, LLY, HZNP: Large Outflows Detected at ETF", "The Math Shows IYH Can Go To $169", "3 Top Biotech Stocks to Buy on Sale", "Can Jazz Pharmaceuticals Be a Top Choice for Value Investors?", "Can Jazz Pharmaceuticals Be a Top Choice for Value Investors?", "5 Biotech Stocks You'll Want to Watch in the 1st Quarter", "Jazz Begins Phase III Study for Label Expansion of Defitelio", "Start the New Year off Right with 3 Best Biotech Stocks", "Here's Why Jazz Pharmaceuticals PLC Fell Out of Tune and Lost 22% in 2016", "4 Top Stocks on Sale This Winter", "3 Most Unbelievably Undervalued Biotech Stocks", "3 Top Healthcare Stocks You've Been Overlooking", "Jazz Completes Patient Enrollment in JZP-110 Narcolepsy Trial", "Jazz Pharma (JAZZ) Q3 Earnings Top, Sales Lag Estimates", "5 Sectors Poised to Benefit From Donald Trump's Victory", "After-Hours Earnings Report for November 8, 2016 : CXO, DOX, TRIP, ZAYO, ASH, JAZZ, VSAT, CPA, CVG, PSEC, PFGC, ILG", "Pricing Concerns Push Jazz Pharmaceuticals PLC Down 10% in October", "Jazz Pharma (JAZZ) Q3 Earnings: A Disappointment in Store?", "First Week of February 2017 Options Trading For Jazz Pharmaceuticals (JAZZ)", "3 Top Healthcare Stocks You've Been Overlooking", "Jazz Completes Patient Enrollment in JZP-110 Narcolepsy Trial", "3 Top Biotech Stocks to Buy on Sale", "Peek Under The Hood: XPH Has 25% Upside", "The Cheapest Stocks in Biotech", "3 Mid-Cap Healthcare Stocks You Can Buy Right Now", "Weakness Seen in Jazz Pharmaceuticals (JAZZ) Estimates: Should You Stay Away?", "3 Healthcare Stocks That Are Looking Cheap", "Jazz Initiates Rolling NDA for Leukemia Candidate Vyxeos", "Jazz (JAZZ) Q2 Earnings Up Y/Y, Lowers Earnings Outlook", "Earnings Reaction History: Jazz Pharmaceuticals, Inc., 11.1% Follow-Through Indicator, 2.5% Sensitive", "After-Hours Earnings Report for August 9, 2016 : DIS, MYL, MDVN, JAZZ, VSAT, TAHO, XON, DPLO, PCTY, FLTX, FSIC, WAGE", "Jazz (JAZZ) Q2 Earnings: Will the Stock Disappoint?", "This Could Be the Next Big Pharma Buyout", "Forget the Me-Too Cancer Drugs -- These Breakthroughs Are Where You Want to Invest", "PPH's Holdings Imply 16% Gain Potential", "Why Celator Pharmaceuticals Is Up 1,610% in 2016", "Interesting JAZZ Put And Call Options For August 5th", "First Week of August 19th Options Trading For Jazz Pharmaceuticals (JAZZ)", "Jazz Pharmaceuticals Offers HAL Study Data on JZP-110", "4 Cancer Drug Developers You Need to Have on Your Radar This Year", "Notable ETF Outflow Detected - XPH, RLYP, AKRX, JAZZ", "Sum Up The Parts: PXMG Could Be Worth $34", "JAZZ August 26th Options Begin Trading", "Why Celator Pharmaceuticals Is Up 1,610% in 2016", "Interesting JAZZ Put And Call Options For August 5th", "First Week of August 19th Options Trading For Jazz Pharmaceuticals (JAZZ)", "Jazz Pharmaceuticals Offers HAL Study Data on JZP-110", "4 Cancer Drug Developers You Need to Have on Your Radar This Year", "Notable ETF Outflow Detected - XPH, RLYP, AKRX, JAZZ", "Mid-Morning Market Update: Markets Edge Higher; Medtronic Earnings Top Views", "3 Cheap Biotech Stocks You Can Buy Now", "Why Celator Pharmaceuticals Shares Skyrocketed 100% in May", "Company News for June 01, 2016", "Midday Update: Stocks Turn Defensive After Digesting Mixed Economic Data", "Mid-Day Market Update: Dow Falls Over 50 Points; Celator Pharmaceuticals Shares Jump After Acquisition Announcement By Jazz Pharmaceuticals", "Is 70% an Excessive Premium for Celator Pharmaceuticals Inc? (CPXX JAZZ)", "Why Celator Pharmaceuticals Shares Are Skyrocketing Today", "Mid-Morning Market Update: Markets Edge Higher; Medtronic Earnings Top Views", "3 Cheap Biotech Stocks You Can Buy Now", "These Billionaires Just Made a Killing on Celator. Here's What Else They've Been Buying", "Drug Stocks Reporting on May 10: XON, ARIA, CPRX & More", "Is a Surprise Coming for Jazz Pharmaceuticals (JAZZ) This Earnings Season?", "What's in the Cards for Catalyst (CPRX) in Q1 Earnings?", "Jazz Pharmaceuticals Breaks Below 200-Day Moving Average - Notable for JAZZ", "ARIAD (ARIA) to Report Q1 Earnings: Will the Stock Surprise?", "Allergan (AGN) Q1 Earnings: Will the Stock Disappoint?", "Earnings Reaction History: Jazz Pharmaceuticals, Inc., 11.1% Follow-Through Indicator, 2.7% Sensitive", "After-Hours Earnings Report for May 10, 2016 : DIS, EA, SLF, JAZZ, ALB, KGC, NUAN, YPF, XON, PSEC, FOSL, FNGN", "Teva (TEVA) Q1 Earnings: Will the Stock Deliver a Surprise?", "Intrexon (XON): Stock Likely to Beat Estimates in Q1 Earnings", "Will BioDelivery (BDSI) Disappoint Estimates in Q1 Earnings?", "What's in the Cards for Synta (SNTA) This Earnings Season?", "Inovio (INO): What's in Store for the Stock in Q1 Earnings?", "Kite (KITE) to Report Q1 Earnings: Will the Stock Disappoint?", "Immune Design (IMDZ) Q1 Earnings: What Awaits the Stock?", "Jazz (JAZZ) Q1 Earnings: A Beat in the Cards for the Stock?", "Arena (ARNA) Q1 Earnings: What's in Store for the Stock?", "What Awaits Puma Biotechnology (PBYI) in Q1 Earnings?", "Intercept (ICPT): Stock Likely to Disappoint in Q1 Earnings", "Repros (RPRX) Q1 Earnings: What's in Store for the Stock?", "Geron (GERN) Q1 Earnings: What's in Store for the Stock?", "Conatus (CNAT): Can the Stock Surprise in Q1 Earnings?", "What's in Store for Horizon (HZNP) This Earnings Season?", "Juno (JUNO) Q1 Earnings: What's in Store for the Stock?", "Endo (ENDP) Q1 Earnings: What's in Store for the Stock?", "Zoetis (ZTS): Stock Likely to Beat on Earnings in Q1 Again?", "AmerisourceBergen (ABC) Q2 Earnings: Stock to Surprise?", "Exelixis (EXEL): What's Ahead for the Stock in Q1 Earnings?", "Endocyte (ECYT): What Awaits the Stock in Q1 Earnings?", "What's Up at GW Pharmaceuticals (GWPH) in Q2 Earnings?", "What's in Store for Agios (AGIO) This Earnings Season?", "Here's Why Jazz Pharmaceuticals PLC Was on the Receiving End of a 15% Boost in April", "Jazz Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for JAZZ", "Jazz's Hepatic VOD Drug Defitelio Gains FDA Nod, Shares Up", "Noteworthy Wednesday Option Activity: SYNA, JAZZ, MXIM", "The Implied Analyst 12-Month Target For EUSA", "McKesson (MCK) Q4 Earnings: Stock Likely To Disappoint", "Radius Health (RDUS): Stock to Surprise in Q1 Earnings?", "Commit To Purchase Jazz Pharmaceuticals At $80, Earn 6.5% Annualized Using Options", "Jazz Tops Q4 Earnings, Revenues Up Y/Y, Gives 2016 View", "The 5-Minute Guide to Jazz Pharmaceuticals PLC", "Earnings Reaction History: Jazz Pharmaceuticals, Inc., 20.0% Follow-Through Indicator, 3.2% Sensitive", "After-Hours Earnings Report for February 23, 2016 : EIX, VRSK, EXR, JAZZ, Y, FSLR, WTR, DXCM, CPRT, CAR, HLS, CONE", "Jazz Pharmaceuticals Enters Oversold Territory (JAZZ)", "3 Reasons Jazz Pharmaceuticals Stock Could Rise in 2016", "The Most Important FDA Decision We're Watching This Quarter", "Commit To Purchase Jazz Pharmaceuticals At $80, Earn 6.5% Annualized Using Options", "Jazz Tops Q4 Earnings, Revenues Up Y/Y, Gives 2016 View", "The 5-Minute Guide to Jazz Pharmaceuticals PLC", "Jazz's Q3 Earnings & Revenues Grow Y/Y; Trims 2015 Outlook", "Earnings Reaction History: Jazz Pharmaceuticals, Inc., 22.2% Follow-Through Indicator, 3.3% Sensitive", "Ignore Regeneron Pharmaceuticals, Inc: Here Are 3 Better Buys Right Now", "Jazz's Phase III Data on Defibrotide Published in ASH Journal", "Why Flamel Technologics S.A. Tumbled 15% Today", "3 Companies That Could Become Tax Inversion Targets", "These Biotech Stocks May Start Paying Dividends in 2016", "3 Great Stocks on Sale", "Jazz's Defibrotide under FDA Priority Review, Shares Up", "Jazz Pharmaceuticals (JAZZ) Crumbles: Stock Falls by 7.7%", "After-Hours Earnings Report for November 9, 2015 : IFF, JAZZ, LEAF, UGI, LGF, OPK, XON, RAX, RARE, APU, VSAT, WWD", "3 Stocks to Buy Now in Biotech", "Better Buy Now: Medivation Inc vs Jazz Pharmaceuticals", "First Week of JAZZ June 2016 Options Trading", "3 Value Stocks Near 52-Week Lows Worth Buying", "Health Care Sector Update for 10/09/2015: JAZZ, LXRX, IPCI", "Jazz's Defibrotide under FDA Priority Review, Shares Up", "Jazz Pharmaceuticals Beats on Earnings, Misses on Revenues - Stocks in the News", "3 Mid-Cap Biotechs We're Excited About", "EWG, DWAQ: Big ETF Inflows", "Wakefulness Drug Xyrem Keeps Jazz Pharmaceuticals Up", "Commit To Buy Jazz Pharmaceuticals At $115, Earn 6.8% Using Options", "Jazz Pharmaceuticals (JAZZ) Shares Cross Below 200 DMA", "Jazz Pharmaceuticals' Sleep Disorder Drug Enters Phase III - Analyst Blog", "Jazz Pharmaceuticals Larger Than S&P 500 Component Coca-Cola Enterprises", "QuickLogic: A Venture Capital-Style Opportunity For Public Market Investors", "This Winning Biotech Stock Looks Like a Buy", "EWG, DWAQ: Big ETF Inflows", "Wakefulness Drug Xyrem Keeps Jazz Pharmaceuticals Up", "Commit To Buy Jazz Pharmaceuticals At $115, Earn 6.8% Using Options", "Jazz Pharmaceuticals (JAZZ) Shares Cross Below 200 DMA", "Jazz Pharmaceuticals' Sleep Disorder Drug Enters Phase III - Analyst Blog", "This New Hedge Fund Strategy Just Might Be Crazy Enough To Work", "Will This Hedge Fund Manager Bring Down Your Biotech Stocks?", "Why Shares of Flamel Technologies SA Bolted Higher Today", "Jazz Pharmaceuticals Misses on Q1 Earnings, Affirms View - Analyst Blog", "Earnings Reaction History: Jazz Pharmaceuticals, Inc., 20.0% Follow-Through Indicator, 3.0% Sensitive", "After-Hours Earnings Report for May 7, 2015 : CBS, CERN, MNST, CA, MHK, BAP, NVDA, TSO, JAZZ, MDVN, MCHP, MTD", "2 Stocks to Buy in a Biotech Crash", "Big Pharma Comes Under Attack From a New Hedge Fund Strategy", "This New Hedge Fund Strategy Just Might Be Crazy Enough To Work", "Will This Hedge Fund Manager Bring Down Your Biotech Stocks?", "Why Shares of Flamel Technologies SA Bolted Higher Today", "Jazz Pharmaceuticals Up on U.S. Approval of Xyrem REMS - Analyst Blog", "Company News for February 26, 2015 - Corporate Summary", "Play This \"Hidden\" M&A Boom \u2013 and Beat the Market for the Next Two Years", "Jazz Pharmaceuticals Tops Q4 Earnings, Provides Guidance - Analyst Blog", "Earnings Reaction History: Jazz Pharmaceuticals, Inc., 20.0% Follow-Through Indicator, 2.9% Sensitive", "After-Hours Earnings Report for February 24, 2015 : HPQ, EIX, CLR, VRSK, JAZZ, NLY, AWK, RRC, Y, FSLR, NDSN, CPRT", "Commit To Purchase Jazz Pharmaceuticals At $110, Earn 6.6% Using Options", "Pfizer Inc. Has a Growth Problem -- Here Are 3 Ways to Change That", "Jazz Pharmaceuticals Starts Defibrotide Rolling NDA Filing - Analyst Blog", "Health Care Sector Update for 12/12/2014: JAZZ,CCXI,EPRS", "JAZZ Pharmaceuticals Slips After Dosing Issue on JZP-386 - Analyst Blog", "Jazz Pharmaceuticals (JAZZ) Starts Late-Stage Study on Xyrem - Analyst Blog", "5 Axes to Chop Better Stocks - Investment Ideas", "3 Biotech Growth Stocks You Can Buy Right Now", "Riding The Bull Market With These 2 Momentum ETFs", "Top Pharmaceutical Stocks to Buy for 2015", "Jazz Pharmaceuticals Starts Defibrotide Rolling NDA Filing - Analyst Blog", "Health Care Sector Update for 12/12/2014: JAZZ,CCXI,EPRS", "JAZZ Pharmaceuticals Slips After Dosing Issue on JZP-386 - Analyst Blog", "Jazz Pharmaceuticals (JAZZ) Starts Late-Stage Study on Xyrem - Analyst Blog", "5 Axes to Chop Better Stocks - Investment Ideas", "After-Hours Earnings Report for November 4, 2014 : FOXA, PXD, FOX, DVN, ATVI, SBAC, PBA, OKE, TRIP, JAZZ, PCYC, XEC", "Bullish Two Hundred Day Moving Average Cross - JAZZ", "Is Jazz Pharmaceuticals (JAZZ) a Great Growth Stock? - Tale of the Tape", "Jazz Pharmaceuticals Uses New Cash To Buy For Growth", "Top Fund Buys: Chipotle, Allergan, Jazz, Gilead", "Shire Resolves Litigation Related to Vyvanse, Adderall XR - Analyst Blog", "OPKO Health (OPK) Reports Positive Data on Rayaldee Trial - Analyst Blog", "Alcobra Finishes Follow-up Visits on Phase III Trial on MDX - Analyst Blog", "Dynavax (DVAX) Completes Enrolment for Study on Heplisav - Analyst Blog", "Should You Invest in Corporate Tax Inversions?", "Concert Pharmaceuticals Announces Positive CTP-354 Data - Analyst Blog", "Three Stocks Top-Performing Funds Like: Facebook Baidu Gilead", "Jazz Pharmaceuticals (JAZZ) Shares March Higher, Can It Continue? - Tale of the Tape", "Stock Market News for August 14, 2014 - Market News", "Jazz Pharmaceuticals (JAZZ) in Focus: Stock Surges 8.8% - Tale of the Tape", "Sector Update: Health Care", "Sector Update: Health-Care Shares Mixed Pre-Market; TearLab Sheds 10% on Weak Q2 Results", "Jazz Pharmaceuticals (JAZZ) Jumps: Stock Moves 5.2% Higher - Tale of the Tape", "Jazz Pharmaceuticals (JAZZ) in Focus: Stock Rises 7.1% - Tale of the Tape", "First Week of March 2015 Options Trading For Jazz Pharmaceuticals (JAZZ)", "Jazz Pharmaceuticals/Concert Pharmaceuticals Start Study - Analyst Blog", "Concert Pharmaceuticals' Shares Slip Despite Favorable FDA Meeting - Analyst Blog", "Biotech Stock Roundup: Regado Plunges on Study Update, Jazz Gains on Product Acquisition Deal - Analyst Blog", "Raptor Pharmaceuticals CEO to Retire, Appoints Successor - Analyst Blog", "iShares U.S. Pharmaceuticals ETF Experiences Big Outflow", "Jazz Pharmaceuticals Public Limited Company (JAZZ) in Focus: Stock Moves 6.9% Higher - Tale of the Tape", "Earnings Up at Jazz Pharmaceuticals, Revenue Guidance Raised - Analyst Blog", "Momentum bulls return to Jazz", "Tuesday's ETF Movers: GDXJ, XPH", "Positive Phase IIb Data from Jazz Pharma - Analyst Blog", "First Week of JAZZ July 19th Options Trading", "Earnings Up at Jazz Pharma, Guidance Reiterated - Analyst Blog", "Notable ETF Outflow Detected - VBK, ARCP, JAZZ, WAB", "VBK, ARCP, JAZZ, WAB: Large Outflows Detected at ETF", "Jazz Pharmaceuticals to Buy Rights to Defibrotide, Shares Up - Analyst Blog", "Weekly Insider Sells Highlight: JAZZ, HD, ESRX, SCI", "Sector Update: Healthcare Shares Flat to Higher Pre-Market; BioCryst Q4 Results Mixed", "Sector Update: Healthcare", "Late Selloff Nips Healthcare Stocks; Jazz Pharmaceuticals Falls After Missing Q4 Expectations, Downgrade", "Sector Update: Healthcare", "After-Hours Earnings Report for February 25, 2014 : EIX, AVGO, RRC, SBAC, WFT, VRSK, NLY, JAZZ, CBI, Y, QEP, FSLR", "First Trust Health Care AlphaDEX Fund Experiences Big Inflow", "Wall Street Positive On Hopes For Global Stimulus", "Bull of the Day: Endocyte (ECYT) - Bull of the Day", "First Trust Health Care AlphaDEX Fund Experiences Big Inflow", "Jazz Pharmaceuticals Public Limited Company (JAZZ): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report", "Celgene Provides Rosy Long-term Projection - Analyst Blog", "Sucampo (SCMP) Worth Watching: Stock Rises 11.9% - Tale of the Tape", "Cadence Pharmaceuticals Inc. (CADX) Soars: Stock Adds 13.0% in Session - Tale of the Tape", "IGI, Laboratories (IG) Soars: Stock Adds 10.4% in Session - Tale of the Tape", "Dendreon Up on Prelim Q4 Results - Analyst Blog", "AMAG's Feraheme Revs Look Good - Analyst Blog", "Jazz Pharma Acquires Sleep Drug - Analyst Blog", "Avanir Gives Preliminary Q1 Update - Analyst Blog", "Tesaro (TSRO) Jumps: Stock Moves 8.1% Higher - Tale of the Tape", "Flamel Technologies (FLML) in Focus: Stock Jumps 8.6% - Tale of the Tape", "Repros Continues to Gain on Androxal News - Analyst Blog", "ENDP Agrees to Sell HealthTronics Unit - Analyst Blog", "Receptos (RCPT) in Focus: Stock Moves 12.6% Higher - Tale of the Tape", "Zogenix (ZGNX) Worth Watching: Stock Surges 16.5% - Tale of the Tape", "Abraxane Label Expansion Lifts Celgene - Analyst Blog", "Bullish on Actelion - Analyst Blog", "RedHill Biopharma Sells ADS Again - Analyst Blog", "Flamel Technologies SA (FLML) Jumps: Stock Adds 8.7% - Tale of the Tape", "ARIAD to Present at JPM Conference - Analyst Blog", "Intercept to Provide Update on Pipeline - Analyst Blog", "BioCryst Attains 52-Week High - Analyst Blog", "Gentium Upgraded to Strong Buy - Analyst Blog", "Acura Confirms $10M Loan Agreement - Analyst Blog", "Bullish on Actelion - Analyst Blog", "RedHill Biopharma Sells ADS Again - Analyst Blog", "Flamel Technologies SA (FLML) Jumps: Stock Adds 8.7% - Tale of the Tape", "Perrigo Maintained at Neutral - Analyst Blog", "Pluristem Touches 52-Week High - Analyst Blog", "Bullish on Gilead - Analyst Blog", "Valeant Attains 52-Week High - Analyst Blog", "ChemoCentryx (CCXI) Jumps: Stock Up 5.7% - Tale of the Tape", "New Patent for SN-38 Conjugates at IMMU - Analyst Blog", "Pipeline Progress at Heat Biologics - Analyst Blog", "Salix Pharma Acquires Santarus - Analyst Blog", "Priority Review for CBST's Antibiotic - Analyst Blog", "Update on Shire-ViroPharma Deal - Analyst Blog", "Update on Amarin's Vascepa - Analyst Blog", "Ventrus Biosciences (VTUS) Jumps: Stock Up 6.8% - Tale of the Tape", "Inovio Pharmaceuticals (INO) Soars: Stock Zooms 20.2% - Tale of the Tape", "Durata Progresses with Dalbavancin - Analyst Blog", "United Therapeutics Surges After FDA Approval - Analyst Blog", "Update on RedHill Biopharma's Pipeline - Analyst Blog", "Update on AstraZeneca's Crestor - Analyst Blog", "Update on Shire-ViroPharma Deal - Analyst Blog", "Update on Amarin's Vascepa - Analyst Blog", "Pipeline Update on Santarus Candidate - Analyst Blog", "Sucampo Reports Data - Analyst Blog", "Update on ARIAD's Iclusig - Analyst Blog", "EU Approves Actelion's Opsumit - Analyst Blog", "Update on BioSpecifics/ Auxilium's Xiaflex - Analyst Blog", "Pipeline Update on Aratana - Analyst Blog", "Update on MDCO's Pipeline - Analyst Blog", "Synergy Pharma Progresses with Plecanatide - Analyst Blog", "Pipeline Update on Santarus Candidate - Analyst Blog", "Sucampo Reports Data - Analyst Blog", "Update on ARIAD's Iclusig - Analyst Blog", "EU Approves Actelion's Opsumit - Analyst Blog", "TESARO Plunges on Study Results - Analyst Blog", "Ariad Pharmaceuticals (ARIA) Catches Eye: Stock Jumps 8.9% - Tale of the Tape", "Athersys, Inc. (ATHX) Jumps: Stock Up 6.9% - Tale of the Tape", "Can-Fite BioPharma (CANF) Soars: Stock Zooms 17.5% - Tale of the Tape", "Pipeline Progress at Athersys - Analyst Blog", "Update on AstraZeneca's Nexium Competition - Analyst Blog", "BioCryst's Peramivir Filed in the U.S. - Analyst Blog", "Update on Glaxo's HIV Drugs - Analyst Blog", "TESARO Plunges on Study Results - Analyst Blog", "Apricus Biosciences (APRI) Soars: Stock Up 10.6% - Tale of the Tape", "Jazz Pharmaceuticals plc (JAZZ) Catches Eye: Stock Rises 8% - Tale of the Tape", "Alimera Sciences (ALIM) Soars: Stock Zooms 62.8% - Tale of the Tape", "pSivida Corp. (PSDV) Jumps: Stock Up 32.0% - Tale of the Tape", "Update on BioLineRx's BL-7010 - Analyst Blog", "Mid-Afternoon Market Update: Textron Rises as Markets Rise Across the Board", "Novartis' Sandoz receives AirFluSal Forspiro approval - Analyst Blog", "BMY to Sell Diabetes Portfolio - Analyst Blog", "Mid-Morning Market Update: Markets Rally; BlackBerry Posts Q3 Loss", "Jazz Pharma to Acquire Gentium - Analyst Blog", "Halozyme Therapeutics (HALO) Jumps: Stock Up 16.6% - Tale of the Tape", "Positive Data on Gilead's Sovaldi - Analyst Blog", "Update on pSivida's Iluvien - Analyst Blog", "RedHill Doses First Patient for ERADICATE Study - Analyst Blog", "Sucampo's Amitiza Progresses - Analyst Blog", "Glaxo/THRX' Drug Gets FDA Nod - Analyst Blog", "Hyperion Therapeutics (HPTX) Jumps: Stock Adds 5.2% - Tale of the Tape", "Ariad Pharmaceuticals (ARIA) Worth Watching: Stock Surges 19.7% - Tale of the Tape", "Halozyme Therapeutics (HALO) Jumps: Stock Up 16.6% - Tale of the Tape", "Positive Data on Gilead's Sovaldi - Analyst Blog", "Update on pSivida's Iluvien - Analyst Blog", "RedHill Doses First Patient for ERADICATE Study - Analyst Blog", "Sucampo's Amitiza Progresses - Analyst Blog", "Glaxo/THRX' Drug Gets FDA Nod - Analyst Blog", "Gilead's Sovaldi Holds Promise - Analyst Blog", "NuPathe, Inc. (PATH) in Focus: Stock Zooms 47.4% - Tale of the Tape", "AcelRx Pharmaceuticals (ACRX) Jumps: Stock Up 17.9% - Tale of the Tape", "Endo to Acquire NuPathe - Analyst Blog", "Update on Alexion's Voluntary Recall - Analyst Blog", "Update on Endo's AMS Unit - Analyst Blog", "Peregrine Reports In-Line Loss - Analyst Blog", "Data on AstraZeneca's Lesinurad - Analyst Blog", "ImmunoGen Amends Lilly Agreement - Analyst Blog", "SUPN Presents Data on Drugs at AES - Analyst Blog", "BioSpecifics Technologies Corp. (BSTC) in Focus: Stock Moves 6.5% Higher - Tale of the Tape", "Puma Biotechnology (PBYI) Jumps: Stock Up 11.7% - Tale of the Tape", "ARIAD Loses as EMA Deliberates on Iclusig - Analyst Blog", "Positive Data on Shire's Lifitegrast - Analyst Blog", "Anacor Pharmaceuticals (ANAC) Jumps: Stock Rises 5.7% - Tale of the Tape", "Coronado Biosciences (CNDO) Jumps: Stock Adds 13.4% in Session - Tale of the Tape", "Celgene Rises on Positive Revlimid Data - Analyst Blog", "Data Presented by Celgene - Analyst Blog", "BioSpecifics Technologies Corp. (BSTC) in Focus: Stock Moves 6.5% Higher - Tale of the Tape", "Puma Biotechnology (PBYI) Jumps: Stock Up 11.7% - Tale of the Tape", "ARIAD Loses as EMA Deliberates on Iclusig - Analyst Blog", "Positive Data on Shire's Lifitegrast - Analyst Blog", "Anacor Pharmaceuticals (ANAC) Jumps: Stock Rises 5.7% - Tale of the Tape", "Coronado Biosciences (CNDO) Jumps: Stock Adds 13.4% in Session - Tale of the Tape", "Update on KaloBios' KB004 - Analyst Blog", "Update on Pacira's Exparel - Analyst Blog", "AstraZeneca Wins Prilosec Damages - Analyst Blog", "NDA for AcelRx's Zalviso Accepted - Analyst Blog", "Impax Settles Litigation with Purdue Pharma - Analyst Blog", "JAZZ Briefs at Healthcare Conference - Analyst Blog", "Final Guidance from NICE for pSivida's Iluvien - Analyst Blog", "Receptos (RCPT) in Focus: Stock Moves 21.8% Higher - Tale of the Tape", "Galectin Therapeutics (GALT) in Focus: Stock Moves Up 13.2% - Tale of the Tape", "Data on NVO's Diabetes Drugs - Analyst Blog", "Forest Labs Up on Strategic Initiatives - Analyst Blog", "Strength Seen in Lannett Company (LCI): Stock Gains 8.7% - Tale of the Tape", "Can the Rally in Jazz Pharmaceuticals plc (JAZZ) Shares Continue? - Tale of the Tape", "Actelion's Update on Opsumit - Analyst Blog", "Allergan Sells Off Obesity Business - Analyst Blog", "Cadence Pharmaceuticals Inc. (CADX) Jumps: Stock Rises 6.2% - Tale of the Tape", "Athersys to Raise Funds - Analyst Blog", "Impax Labs Attains 52-Week High - Analyst Blog", "Back to Neutral on Endo Health - Analyst Blog", "AMAG Raised to Strong Buy - Analyst Blog", "BioScrip (BIOS) Jumps: Stock Moves 17.3% Higher - Tale of the Tape", "Pipeline Progress at Ventrus - Analyst Blog", "Zogenix (ZGNX) Worth a Look: Stock Adds 7.3% in Session - Tale of the Tape", "Aeterna Zentaris Closes Public Offering - Analyst Blog", "Enanta Pharmaceuticals (ENTA) Looks Good: Stock Adds 6.2% - Tale of the Tape", "Good News for Apricus from Italy - Analyst Blog", "Alnylam Earns Milestone Payment - Analyst Blog", "Strength Seen in Ariad Pharmaceuticals (ARIA): Stock Zooms 35.5% - Tale of the Tape", "Continuation of ARIAD's Iclusig in EU - Analyst Blog", "Data on Auxilium Pharma's Xiaflex - Analyst Blog", "Regulatory Setback for Forest/Gedeon - Analyst Blog", "Ligand Pharmaceuticals (LGND) Jumps: Stock Rises 5.5% - Tale of the Tape", "Update from QLTI, Shares up - Analyst Blog", "AMAG Upgraded to Strong Buy - Analyst Blog", "Athersys Narrows Loss, Shares Rise - Analyst Blog", "QLT (QLTI) Surges: Stock Moves 11.8% Higher - Tale of the Tape", "Orphan Drug Status for Gentium's Defitelio - Analyst Blog", "Jazz Pharma Attains 52-Week High - Analyst Blog", "Dynavax Technologies (DVAX) in Focus: Stock Moves 5.8% Higher - Tale of the Tape", "BioLineRx's Pipeline Holds Promise - Analyst Blog", "BioSpecifics Technologies (BSTC) Looks Good: Stock Moves 9.5% Higher - Tale of the Tape", "Market Reacts to Vanda's Hetlioz - Analyst Blog", "Loss Widens at Apricus - Analyst Blog", "Narrower Loss at Orexigen in Q3 - Analyst Blog", "FDA Accepts NPS Pharma's sNDA - Analyst Blog", "Anacor Rises on Positive Data - Analyst Blog", "Can The Uptrend Continue for Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)? - Tale of the Tape", "Synergy Pharma's Q3 Loss Narrower than Expected - Analyst Blog", "IGI Laboratories (IG) in Focus: Stock Surges 14.5% - Tale of the Tape", "Narrow-than-Expected Loss at Pernix - Analyst Blog", "Jazz Pharmaceuticals (JAZZ) Worth Watching: Stock Rises 8.7% - Tale of the Tape", "Narrower Loss at Orexigen in Q3 - Analyst Blog", "FDA Accepts NPS Pharma's sNDA - Analyst Blog", "Anacor Rises on Positive Data - Analyst Blog", "Can The Uptrend Continue for Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)? - Tale of the Tape", "Actelion's Opsumit Cleared in Canada - Analyst Blog", "Vanda Shoots Up Ahead of FDA Panel - Analyst Blog", "Narrower Q3 Loss at Supernus - Analyst Blog", "AstraZeneca to Invest in New Zoladex Facility - Analyst Blog", "Trade the Earnings: Jazz Pharmaceuticals, Inc.", "Stock-Picking Secrets of the Whales - Weekend Wisdom", "GSK, Genmab Seek Arzerra EU Approval - Analyst Blog", "Narrower-than-Expected Loss at ArQule - Analyst Blog", "Valeant's Jublia Approved in Canada - Analyst Blog", "Good News for Valeant - Analyst Blog", "Update on NPS Pharma's Portfolio - Analyst Blog", "Data on ArQule's Tivantinib - Analyst Blog", "Data on GW Pharma's Sativex - Analyst Blog", "Update on Pacira's Exparel - Analyst Blog", "Update on Anacor's Tavaborole - Analyst Blog", "Incyte Progresses with JAK Inhibitors - Analyst Blog", "Valeant's Jublia Approved in Canada - Analyst Blog", "Good News for Valeant - Analyst Blog", "Update on NPS Pharma's Portfolio - Analyst Blog", "Data on ArQule's Tivantinib - Analyst Blog", "Data on GW Pharma's Sativex - Analyst Blog", "Update on Pacira's Exparel - Analyst Blog", "Update on Anacor's Tavaborole - Analyst Blog", "Incyte Progresses with JAK Inhibitors - Analyst Blog", "Label Expansion for Roche's Perjeta - Analyst Blog", "Glaxo to Divest Arixtra and Fraxiparine - Analyst Blog", "Cempra (CEMP) Worth a Look: Stock Up 6.1% - Analyst Blog", "Data on Cytori's Cell Therapy - Analyst Blog", "Data on KaloBios' KB001 Published - Analyst Blog", "Protalix Raises Funds - Analyst Blog", "Coronado Biosciences' TSO in Phase II study - Analyst Blog", "Update on Amarin Study - Analyst Blog", "VIVUS' Hopes Tied to Qsymia - Analyst Blog", "Synageva Prices Public Offering - Analyst Blog", "Strength Seen in PTC Therapeutics (PTCT): Stock Surges 25.7% - Analyst Blog", "Data on Cytori's Cell Therapy - Analyst Blog", "Data on KaloBios' KB001 Published - Analyst Blog", "Protalix Raises Funds - Analyst Blog", "Coronado Biosciences' TSO in Phase II study - Analyst Blog", "Encouraging Data on Kythera's ATX-101 - Analyst Blog", "Roche and Inovio Tie Up - Analyst Blog", "Encouraging Data on Xenoport's XP23829 - Analyst Blog", "Catalyst Pharma Raises Funds - Analyst Blog", "Novartis Ties Up With Regenerex - Analyst Blog", "Standard Review for MRK Fertility Drug - Analyst Blog", "Encouraging Data on Oncolytics' Reolysin - Analyst Blog", "Update on XenoPort's Horizant - Analyst Blog", "Data on Novartis' Ultibro Breezhaler - Analyst Blog", "Roche and Inovio Tie Up - Analyst Blog", "Encouraging Data on Xenoport's XP23829 - Analyst Blog", "Catalyst Pharma Raises Funds - Analyst Blog", "Novartis Ties Up With Regenerex - Analyst Blog", "Standard Review for MRK Fertility Drug - Analyst Blog", "Encouraging Data on Oncolytics' Reolysin - Analyst Blog", "Update on XenoPort's Horizant - Analyst Blog", "VIVUS Gets a New CEO - Analyst Blog", "Setback for Glaxo's Cancer Pipeline - Analyst Blog", "Otsuka Pharma to Acquire Astex Pharma, Shares Up - Analyst Blog", "Data on Cempra's Solithromycin - Analyst Blog", "Encouraging Data on Roche's Lampalizumab - Analyst Blog", "Swissmedic Negative on Apricus' Vitaros - Analyst Blog", "European Approval for Glaxo's Tafinlar - Analyst Blog", "Sanofi Unveils Bond Issue Pricing - Analyst Blog", "Setback for ArQule - Analyst Blog", "Data on Novartis' RLX030 - Analyst Blog", "EU Nod for Roche's New Formulation of Herceptin - Analyst Blog", "Aradigm, Grifols Collaborate - Analyst Blog", "Encouraging Data on Roche's Lampalizumab - Analyst Blog", "Swissmedic Negative on Apricus' Vitaros - Analyst Blog", "Opko Acquires Prolor Biotech - Analyst Blog", "Breakthrough Therapy for Novartis - Analyst Blog", "Abbott Acquires OptiMedica - Analyst Blog", "Hyperion's Loss Narrows Y/Y - Analyst Blog", "Impax Surpasses Earnings Estimates - Analyst Blog", "Loss Widens at Omeros in Q2 - Analyst Blog", "Corcept's Q2 Loss In-Line with Expectations - Analyst Blog", "Setback for Novartis' Afinitor - Analyst Blog", "Positive Results from Fibrocell Science - Analyst Blog", "Breakthrough Therapy for Novartis - Analyst Blog", "Abbott Acquires OptiMedica - Analyst Blog", "Hyperion's Loss Narrows Y/Y - Analyst Blog", "Impax Surpasses Earnings Estimates - Analyst Blog", "OncoGenex OGX-427 in Spruce Study - Analyst Blog", "Loss Widens at VIVUS - Analyst Blog", "Trade the Earnings: Jazz Pharmaceuticals, Inc.", "Valeant Tops on Earnings, Ups Guidance - Analyst Blog", "Jazz Pharma Posts Higher Earnings & Revs - Analyst Blog", "Santarus Tops on Earnings, Revs - Analyst Blog", "In Line Loss at Orexigen in Q2 - Analyst Blog", "Valeant Acquires Bausch + Lomb - Analyst Blog", "OncoGenex OGX-427 in Spruce Study - Analyst Blog", "Loss Widens at VIVUS - Analyst Blog", "Trade the Earnings: Jazz Pharmaceuticals, Inc.", "Valeant Tops on Earnings, Ups Guidance - Analyst Blog", "Arena Pharma's Q2 Earnings Soar - Analyst Blog", "Label Expansion for Novartis' Menveo - Analyst Blog", "VPHM Misses on Earnings & Revs - Analyst Blog", "Aeterna Initiates Phase III Study on AEZS-108 - Analyst Blog", "Wider Loss at CADX in Q2 - Analyst Blog", "Pipeline Progress at Nektar - Analyst Blog", "Q2 Loss at Aegerion Wider than Expected - Analyst Blog", "Shire's Earnings Grow in Q2 - Analyst Blog", "Arena Pharma, CY Biotech Unite for Belviq - Analyst Blog", "Good News for Bayer - Analyst Blog", "Strong 1H13 at Roche, View Backed - Analyst Blog", "Questcor to Start Phase II Study - Analyst Blog", "Earnings Up at The Medicines Co. - Analyst Blog", "Earnings Beat at Alexion, View Upped - Analyst Blog", "Narrower-Than-Expected Loss at BioMarin - Analyst Blog", "Shire's Earnings, Revs Increase in Q2 - Analyst Blog", "Glaxo Revs Up, Earnings Down - Analyst Blog", "Merck's Vorapaxar NDA Accepted - Analyst Blog", "Corcept Makes Ties with Idis - Analyst Blog", "Questcor to Start Phase II Study - Analyst Blog", "Earnings Up at The Medicines Co. - Analyst Blog", "Earnings Beat at Alexion, View Upped - Analyst Blog", "Bristol-Myers Reports In-Line Earnings - Analyst Blog", "Forest Labs Beats on Earnings & Revs - Analyst Blog", "Santarus Progresses Uceris Study - Analyst Blog", "Ligand, Azure Collaborate - Analyst Blog", "Intellipharmaceutics Up on Positive Data - Analyst Blog", "Insmed Prices Public Offering - Analyst Blog", "U.S. Launch of Astellas' Astagraf XL - Analyst Blog", "Pacira Reports New Data - Analyst Blog", "Cadence Pharma Soars Ahead of 2Q - Analyst Blog", "Forest Labs Beats on Earnings & Revs - Analyst Blog", "Santarus Progresses Uceris Study - Analyst Blog", "Ligand, Azure Collaborate - Analyst Blog", "Intellipharmaceutics Up on Positive Data - Analyst Blog", "Insmed Prices Public Offering - Analyst Blog", "U.S. Launch of Astellas' Astagraf XL - Analyst Blog", "Pacira Reports New Data - Analyst Blog", "Cadence Pharma Soars Ahead of 2Q - Analyst Blog", "Chelsea's NDA for Northera Accepted - Analyst Blog", "Positive Data from Emergent's BioThrax - Analyst Blog", "BioDelivery Announces $20M Debt Financing - Analyst Blog", "Warner Chilcott Still in Neutral Lane - Analyst Blog", "Santarus Achieves New 52-Week High - Analyst Blog", "Lilly/Boehringer Candidate Under EU Review - Analyst Blog", "Array - Loxo Collaborate - Analyst Blog", "Prestige Brands Acquires Care Pharma - Analyst Blog", "GW Pharma's Sativex Launched in Italy - Analyst Blog", "Positive Data from Emergent's BioThrax - Analyst Blog", "BioDelivery Announces $20M Debt Financing - Analyst Blog", "Warner Chilcott Still in Neutral Lane - Analyst Blog", "Jazz Pharma Touches 52-Week High - Analyst Blog", "Ariad's Iclusig Approved in EU - Analyst Blog", "Bayer Initiates Phase III Study - Analyst Blog", "Array Begins Phase III Study on MEK162 - Analyst Blog", "pSivida Starts Phase III Study - Analyst Blog", "Zoetis Looking to Expand - Analyst Blog", "Avanir - OptiNose Collaborate - Analyst Blog", "Positive Data from Forest Labs - Analyst Blog", "MannKind Reaches Financing Deal - Analyst Blog", "Yet Another Setback for Bayer/JNJ's Xarelto - Analyst Blog", "Good News for Omeros on OMS302 - Analyst Blog", "Takeda Withdraws MAA for Omontys - Analyst Blog", "pSivida Starts Phase III Study - Analyst Blog", "Zoetis Looking to Expand - Analyst Blog", "Avanir - OptiNose Collaborate - Analyst Blog", "Positive Data from Forest Labs - Analyst Blog", "MannKind Reaches Financing Deal - Analyst Blog", "Astellas/Vical Start TransVax Phase III Study - Analyst Blog", "Avanir Completes PRIME Enrollment - Analyst Blog", "Pluristem/Cha Collaborate in South Korea - Analyst Blog", "US Exclusivity for Raptor's Procysbi - Analyst Blog", "Cytokinetics, Astellas Collaborate - Analyst Blog", "EU Approval for Avanir's Nuedexta - Analyst Blog", "New Study on XOMA/Servier's Gevokizumab - Analyst Blog", "Gilead Retained at Neutral - Analyst Blog", "Evenly Poised on Regeneron - Analyst Blog", "EU Nod for Medivation/Astellas' Xtandi - Analyst Blog", "Pluristem/Cha Collaborate in South Korea - Analyst Blog", "US Exclusivity for Raptor's Procysbi - Analyst Blog", "Cytokinetics, Astellas Collaborate - Analyst Blog", "Data from Hyperion's UCD Drugs - Analyst Blog", "New Data on Novo Nordisk's Tresiba - Analyst Blog", "Theravance's Vibativ Expanded in the US - Analyst Blog", "Positive Data on Infinity's Oncology Candidate - Analyst Blog", "SGEN/Takeda Report Data on Adcetris - Analyst Blog", "Draft Guidance from NICE for pSivida's Iluvien - Analyst Blog", "Raptor Pharma's Procysbi Launched in the US - Analyst Blog", "Takeda Launches Diabetes Drugs - Analyst Blog", "Ruconest Under FDA Review - Analyst Blog", "Nektar's Pain Drug Impresses - Analyst Blog", "Novo Nordisk Patent Found Invalid - Analyst Blog", "Endo Health to Shell Out $54.5 million - Analyst Blog", "SGEN/Takeda Report Data on Adcetris - Analyst Blog", "Draft Guidance from NICE for pSivida's Iluvien - Analyst Blog", "ViroPharma Up on Takeover Rumors - Analyst Blog", "Data on Astex Candidate - Analyst Blog", "Positive Data on Incyte's Jakafi - Analyst Blog", "Ariad's Iclusig in GIST Phase II Study - Analyst Blog", "Valeant Raising Funds - Analyst Blog", "MannKind Completes Afrezza Studies - Analyst Blog", "Good News for Celgene's Revlimid - Analyst Blog", "US Launch of Forest's Namenda XR - Analyst Blog", "Elan Explores Sale Options - Analyst Blog", "XOMA Commences Gevokizumab Study - Analyst Blog", "Positive Data on Incyte/LLY's Baricitinib - Analyst Blog", "Encouraging Data from Bristol-Myers - Analyst Blog", "Acquisitions Add To Jazz Pharma's Diversity", "CELG Presents Positive Long-term Data - Analyst Blog", "Incyte's Jakafi Label Updated - Analyst Blog", "Apricus' Vitaros Approved in Europe - Analyst Blog", "Encouraging Data on Alexion's Soliris - Analyst Blog", "Royalty Offer Remains Unattractive to Elan - Analyst Blog", "Hyperion Acquires Buphenyl Rights - Analyst Blog", "Update on Gentium's Defibrotide - Analyst Blog", "FDA Panel Meeting for Salix Drug - Analyst Blog", "CELG Presents Positive Long-term Data - Analyst Blog", "Incyte's Jakafi Label Updated - Analyst Blog", "Apricus' Vitaros Approved in Europe - Analyst Blog", "Encouraging Data on Alexion's Soliris - Analyst Blog", "Royalty Offer Remains Unattractive to Elan - Analyst Blog", "Hyperion Acquires Buphenyl Rights - Analyst Blog", "Nektar Presents Data on Oncology Candidates - Analyst Blog", "AstraZeneca Resolves Nexium Issue - Analyst Blog", "Label Expansion Sought for AMAG/TKPYY's Rienso - Analyst Blog", "Pfizer in $635 Million Deal - Analyst Blog", "BioLineRx Enrolls First Patient in Study - Analyst Blog", "Positive Data on Bayer/REGN's Eye Drug - Analyst Blog", "Avanir to Expedite AVP-786 Development - Analyst Blog", "Endo to Trim Workforce - Analyst Blog", "Nektar Presents Data on Oncology Candidates - Analyst Blog", "Astellas' Launch Plans for Acofide - Analyst Blog", "Glaxo/Renaissance Ink Deal - Analyst Blog", "Pipeline Setbacks at Sanofi - Analyst Blog", "Idenix Pharma Initiates Phase II Study - Analyst Blog", "Patent Challenge from Perrigo - Analyst Blog", "Array/ONTY to Co-develop ARRY-380 - Analyst Blog", "Postive Interim Data on Pacira's Exparel - Analyst Blog", "Novo Nordisk Seeks IDegLira Approval - Analyst Blog", "Cash and Tysabri Update From Elan - Analyst Blog", "Bayer a Step Closer to Conceptus Buy - Analyst Blog", "Two Top Endo Executives Depart - Analyst Blog", "Omeros Files CTA for aHUS Candidate - Analyst Blog", "Positive Data on Salix's Budesonide Foam - Analyst Blog", "FDA Accepts Omeros' IND for OMS824 - Analyst Blog", "J&J's Promising Pharma Pipeline - Analyst Blog", "Glaxo's Oncology Portfolio Gets a Boost - Analyst Blog", "Promising Data on ONCY's Reolysin - Analyst Blog", "Elan Rejects Royalty Offer Again - Analyst Blog", "Ironwood Pharma Prices Stock Offering - Analyst Blog", "Pfizer Halts Inotuzumab Study - Analyst Blog", "NPS Pharma Prices Offering - Analyst Blog", "Repros to Conduct Phase IIb Trial - Analyst Blog", "AbbVie Extends Galapagos Deal - Analyst Blog", "EU Approval for Bayer/JNJ's Xarelto - Analyst Blog", "Promising Data on ONCY's Reolysin - Analyst Blog", "Sanofi/REGN's Dupilumab Data Published - Analyst Blog", "Generic Launches at Mylan Continue - Analyst Blog", "Additional Patent for Acorda's Ampyra - Analyst Blog", "Elan Provides Strategic Update - Analyst Blog", "FDA Accepts Actavis NDA - Analyst Blog", "Nektar Posts Wider Loss, Maintains View - Analyst Blog", "XenoPort Resumes Horizant Supply - Analyst Blog", "Dr. Reddy's Earnings Increase Y/Y - Analyst Blog", "Synergy Pharma Posts Wider Loss - Analyst Blog", "Good News for Novartis' Ilaris - Analyst Blog", "Forest-Trevena Ink Deal - Analyst Blog", "Jazz Pharma Posts Higher Y/Y Earnings - Analyst Blog", "Lilly Scraps Oncology Candidate - Analyst Blog", "Narrower-than-Expected Loss at MannKind - Analyst Blog", "Merck KGaA Posts Higher Y/Y Earnings - Analyst Blog", "Big move expected from Jazz Pharma", "JAZZ Beats EPS, Misses Sales - Analyst Blog", "After-Hours Earnings Report for February 26, 2013 : PCLN, VNO, EIX, RRC, WFT, VRSK, AVGO, AWK, ERIE, JAZZ, FSLR, BIO", "Jazz Provides Portfolio Update - Analyst Blog", "Jazz Initiates Erwinaze Trial - Analyst Blog", "Jazz Pharma 3Q Earnings In Line - Analyst Blog", "After-Hours Earnings Report for November 8, 2012 : DIS, PSA, JWN, NVDA, MCHP, CFN, ENR, FLT, IGT, GXP, JAZZ, SD", "Teva - Alexza Sign Deal for Adasuve - Analyst Blog", "Markets Consolidate, But Dow Muscles Higher", "JAZZ to Sell Women's Health Suite - Analyst Blog", "Jazz Pharmaceuticals plc Enters Oversold Territory - Tale of the Tape", "After-Hours Earnings Report for August 7, 2012 : DIS, ESRX, ETE, XL, RGP, WR, WRI, BWC, CREE, JAZZ, URS, ANV", "New PowerShares Small-Cap Relative Strength ETF", "Jazz Pharmaceuticals - Aggressive Growth", "Jazz Closes EUSA Acquisition - Analyst Blog", "Jazz Divests Women's Health Suite - Analyst Blog", "10 Biotech Stocks Trading at Deep Discounts to Analyst Target Prices", "Stocks Rebound, Trade Higher Amid Mixed Slate of Earnings; China Data Weighs", "Mid-Day Update: Stocks Shift Higher After Mixed Start; China, Earnings Weigh", "Investing 101: Rallying Healthcare Stocks Being Snapped By The Smart Money", "Market Got You Down? Here Are Ten Good Reasons to Remain Optimistic", "Crisis Creates Rare Opportunity in These 4 Stocks", "July 14th: Top Performing Small Cap Stocks (UFPI, BTH, UTEK, GLUU, JAZZ)", "Jazz Pharmaceuticals plc Enters Oversold Territory - Tale of the Tape", "5 Rallying Biotech Stocks Being Snapped Up By Insiders", "This Quarter's Top Performing Growth Stocks", "Momentum Plays: 14 Stocks Reaching New Highs On Institutional Buying", "Trader sticks with Jazz Pharma", "U.S. Indexes Trade Modestly Higher, Extending Friday's Gains; Deals Top Market News", "Mid-Day Update: Stocks Modestly Higher as Investors Look Ahead to Tomorrow's Fed Minutes", "Bulls target Jazz before FDA ruling", "This Could be the Perfect Biotech Portfolio", "Tuesday Winners: Korn/Ferry International, Jazz Pharma and Carmike Cinemas"], "Elapsed Time": ["3 DAYS AGO", "6 DAYS AGO", "JUN 16, 2020", "JUN 8, 2020", "MAY 28, 2020", "MAY 11, 2020", "MAY 9, 2020", "MAY 6, 2020", "3 DAYS AGO", "MAY 3, 2020", "APR 28, 2020", "APR 27, 2020", "APR 19, 2020", "APR 9, 2020", "MAR 26, 2020", "MAR 25, 2020", "MAY 6, 2020", "MAR 23, 2020", "MAR 18, 2020", "MAR 16, 2020", "MAR 15, 2020", "MAR 9, 2020", "MAR 9, 2020", "MAR 6, 2020", "MAR 24, 2020", "FEB 26, 2020", "FEB 24, 2020", "FEB 21, 2020", "FEB 21, 2020", "FEB 20, 2020", "FEB 19, 2020", "FEB 17, 2020", "FEB 26, 2020", "FEB 14, 2020", "FEB 14, 2020", "FEB 5, 2020", "FEB 3, 2020", "JAN 19, 2020", "JAN 17, 2020", "JAN 10, 2020", "FEB 16, 2020", "JAN 6, 2020", "DEC 19, 2019", "DEC 19, 2019", "DEC 18, 2019", "DEC 15, 2019", "DEC 2, 2019", "NOV 26, 2019", "JAN 7, 2020", "JAN 6, 2020", "DEC 19, 2019", "OCT 8, 2019", "SEP 30, 2019", "SEP 26, 2019", "AUG 27, 2019", "NOV 26, 2019", "AUG 19, 2019", "AUG 7, 2019", "AUG 7, 2019", "JUL 30, 2019", "JUL 14, 2019", "JUN 27, 2019", "JUN 27, 2019", "AUG 20, 2019", "AUG 19, 2019", "AUG 7, 2019", "AUG 7, 2019", "MAR 19, 2019", "MAR 12, 2019", "MAR 12, 2019", "MAY 8, 2019", "MAY 8, 2019", "APR 25, 2019", "FEB 28, 2019", "FEB 27, 2019", "FEB 27, 2019", "FEB 26, 2019", "FEB 26, 2019", "MAR 10, 2019", "FEB 12, 2019", "FEB 12, 2019", "FEB 6, 2019", "JAN 28, 2019", "JAN 10, 2019", "JAN 6, 2019", "JAN 4, 2019", "FEB 20, 2019", "FEB 12, 2019", "FEB 12, 2019", "FEB 6, 2019", "DEC 17, 2018", "DEC 11, 2018", "DEC 6, 2018", "DEC 26, 2018", "NOV 15, 2018", "NOV 13, 2018", "NOV 9, 2018", "NOV 8, 2018", "NOV 7, 2018", "NOV 6, 2018", "NOV 6, 2018", "NOV 29, 2018", "NOV 1, 2018", "OCT 15, 2018", "OCT 12, 2018", "OCT 11, 2018", "OCT 10, 2018", "SEP 20, 2018", "SEP 17, 2018", "NOV 6, 2018", "NOV 1, 2018", "OCT 15, 2018", "OCT 12, 2018", "AUG 21, 2018", "AUG 20, 2018", "AUG 14, 2018", "AUG 8, 2018", "SEP 13, 2018", "SEP 6, 2018", "AUG 28, 2018", "AUG 27, 2018", "AUG 21, 2018", "AUG 20, 2018", "AUG 2, 2018", "AUG 2, 2018", "AUG 8, 2018", "AUG 7, 2018", "AUG 7, 2018", "JUL 27, 2018", "JUL 9, 2018", "JUL 9, 2018", "JUL 6, 2018", "JUL 6, 2018", "AUG 1, 2018", "JUL 2, 2018", "JUN 29, 2018", "JUN 28, 2018", "JUN 19, 2018", "JUN 19, 2018", "JUN 18, 2018", "JUN 15, 2018", "JUL 3, 2018", "JUL 2, 2018", "JUN 29, 2018", "JUN 28, 2018", "JUN 19, 2018", "JUN 19, 2018", "JUN 18, 2018", "JUN 15, 2018", "JUL 3, 2018", "JUN 7, 2018", "MAY 22, 2018", "MAY 16, 2018", "MAY 9, 2018", "MAY 9, 2018", "MAY 8, 2018", "FEB 21, 2018", "MAY 2, 2018", "APR 12, 2018", "APR 2, 2018", "MAR 16, 2018", "MAR 8, 2018", "FEB 28, 2018", "FEB 27, 2018", "FEB 21, 2018", "MAY 2, 2018", "FEB 7, 2018", "JAN 26, 2018", "JAN 15, 2018", "JAN 14, 2018", "JAN 5, 2018", "DEC 22, 2017", "DEC 21, 2017", "FEB 12, 2018", "DEC 19, 2017", "NOV 9, 2017", "NOV 8, 2017", "NOV 7, 2017", "NOV 3, 2017", "SEP 16, 2017", "OCT 27, 2017", "OCT 17, 2017", "OCT 10, 2017", "OCT 6, 2017", "OCT 5, 2017", "OCT 3, 2017", "AUG 30, 2017", "AUG 30, 2017", "SEP 13, 2017", "SEP 7, 2017", "SEP 5, 2017", "SEP 5, 2017", "AUG 31, 2017", "AUG 30, 2017", "AUG 30, 2017", "AUG 30, 2017", "SEP 13, 2017", "AUG 29, 2017", "AUG 29, 2017", "AUG 29, 2017", "AUG 29, 2017", "AUG 29, 2017", "AUG 29, 2017", "AUG 10, 2017", "AUG 25, 2017", "AUG 22, 2017", "AUG 22, 2017", "AUG 18, 2017", "AUG 17, 2017", "AUG 17, 2017", "AUG 11, 2017", "JUN 16, 2017", "AUG 9, 2017", "AUG 9, 2017", "AUG 8, 2017", "AUG 3, 2017", "JUL 25, 2017", "JUN 27, 2017", "JUN 18, 2017", "JUN 15, 2017", "MAY 10, 2017", "MAY 9, 2017", "MAY 9, 2017", "MAY 3, 2017", "APR 29, 2017", "APR 12, 2017", "APR 10, 2017", "MAY 11, 2017", "MAY 10, 2017", "APR 6, 2017", "APR 5, 2017", "APR 4, 2017", "MAR 31, 2017", "MAR 24, 2017", "APR 7, 2017", "MAR 20, 2017", "MAR 16, 2017", "MAR 1, 2017", "FEB 28, 2017", "FEB 28, 2017", "FEB 24, 2017", "FEB 23, 2017", "MAR 21, 2017", "FEB 9, 2017", "FEB 9, 2017", "FEB 3, 2017", "FEB 1, 2017", "JAN 31, 2017", "JAN 30, 2017", "JAN 30, 2017", "FEB 13, 2017", "JAN 20, 2017", "JAN 19, 2017", "JAN 18, 2017", "JAN 18, 2017", "JAN 8, 2017", "JAN 5, 2017", "JAN 2, 2017", "JAN 27, 2017", "DEC 18, 2016", "NOV 29, 2016", "NOV 9, 2016", "NOV 9, 2016", "NOV 8, 2016", "NOV 2, 2016", "NOV 1, 2016", "DEC 27, 2016", "DEC 18, 2016", "SEP 28, 2016", "SEP 26, 2016", "SEP 23, 2016", "SEP 23, 2016", "SEP 10, 2016", "AUG 29, 2016", "OCT 20, 2016", "OCT 4, 2016", "AUG 10, 2016", "AUG 9, 2016", "AUG 9, 2016", "AUG 5, 2016", "JUL 18, 2016", "JUL 17, 2016", "AUG 22, 2016", "JUN 27, 2016", "JUN 23, 2016", "JUN 21, 2016", "JUN 15, 2016", "JUN 15, 2016", "JUN 14, 2016", "JUN 14, 2016", "JUL 7, 2016", "JUN 27, 2016", "JUN 23, 2016", "JUN 21, 2016", "JUN 15, 2016", "JUN 15, 2016", "MAY 31, 2016", "MAY 31, 2016", "JUN 6, 2016", "JUN 4, 2016", "JUN 1, 2016", "MAY 31, 2016", "MAY 31, 2016", "MAY 31, 2016", "MAY 31, 2016", "MAY 31, 2016", "JUN 6, 2016", "MAY 10, 2016", "MAY 9, 2016", "MAY 9, 2016", "MAY 6, 2016", "MAY 6, 2016", "MAY 6, 2016", "MAY 6, 2016", "MAY 10, 2016", "MAY 6, 2016", "MAY 5, 2016", "MAY 5, 2016", "MAY 5, 2016", "MAY 5, 2016", "MAY 4, 2016", "MAY 4, 2016", "MAY 6, 2016", "MAY 4, 2016", "MAY 4, 2016", "MAY 4, 2016", "MAY 3, 2016", "MAY 3, 2016", "MAY 3, 2016", "MAY 3, 2016", "MAY 4, 2016", "MAY 4, 2016", "MAY 2, 2016", "MAY 2, 2016", "MAY 2, 2016", "MAY 2, 2016", "MAY 2, 2016", "MAY 3, 2016", "MAY 3, 2016", "MAY 3, 2016", "APR 13, 2016", "MAR 31, 2016", "MAR 30, 2016", "MAR 10, 2016", "MAY 2, 2016", "MAR 7, 2016", "MAR 1, 2016", "FEB 24, 2016", "FEB 23, 2016", "FEB 23, 2016", "FEB 23, 2016", "FEB 11, 2016", "MAR 8, 2016", "MAR 7, 2016", "MAR 1, 2016", "FEB 24, 2016", "FEB 23, 2016", "NOV 11, 2015", "NOV 9, 2015", "FEB 2, 2016", "FEB 2, 2016", "JAN 8, 2016", "NOV 30, 2015", "NOV 16, 2015", "NOV 15, 2015", "OCT 1, 2015", "SEP 29, 2015", "NOV 9, 2015", "NOV 2, 2015", "OCT 24, 2015", "OCT 21, 2015", "OCT 14, 2015", "OCT 9, 2015", "OCT 1, 2015", "AUG 5, 2015", "SEP 25, 2015", "JUL 28, 2015", "JUL 28, 2015", "JUL 8, 2015", "JUN 29, 2015", "JUN 9, 2015", "MAY 28, 2015", "MAY 12, 2015", "JUL 29, 2015", "JUL 28, 2015", "JUL 28, 2015", "JUL 8, 2015", "JUN 29, 2015", "JUN 9, 2015", "APR 19, 2015", "APR 19, 2015", "MAY 8, 2015", "MAY 8, 2015", "MAY 7, 2015", "MAY 7, 2015", "APR 28, 2015", "APR 26, 2015", "APR 19, 2015", "APR 19, 2015", "MAR 4, 2015", "MAR 4, 2015", "FEB 26, 2015", "FEB 26, 2015", "FEB 25, 2015", "FEB 24, 2015", "FEB 24, 2015", "FEB 10, 2015", "MAR 4, 2015", "DEC 15, 2014", "DEC 12, 2014", "DEC 10, 2014", "DEC 3, 2014", "DEC 3, 2014", "NOV 25, 2014", "NOV 20, 2014", "DEC 20, 2014", "DEC 15, 2014", "DEC 12, 2014", "DEC 10, 2014", "DEC 3, 2014", "DEC 3, 2014", "NOV 4, 2014", "OCT 16, 2014", "NOV 14, 2014", "OCT 3, 2014", "OCT 2, 2014", "SEP 25, 2014", "SEP 24, 2014", "SEP 23, 2014", "SEP 23, 2014", "SEP 16, 2014", "OCT 15, 2014", "SEP 3, 2014", "AUG 21, 2014", "AUG 14, 2014", "AUG 14, 2014", "AUG 8, 2014", "AUG 8, 2014", "AUG 7, 2014", "SEP 8, 2014", "JUL 22, 2014", "JUL 22, 2014", "JUL 9, 2014", "JUL 9, 2014", "JUL 8, 2014", "JUL 7, 2014", "JUL 3, 2014", "AUG 6, 2014", "JUN 23, 2014", "JUN 10, 2014", "JUN 5, 2014", "MAY 20, 2014", "MAY 9, 2014", "APR 8, 2014", "MAR 28, 2014", "MAR 28, 2014", "MAR 11, 2014", "FEB 26, 2014", "FEB 26, 2014", "FEB 26, 2014", "FEB 26, 2014", "FEB 25, 2014", "FEB 24, 2014", "MAR 28, 2014", "FEB 12, 2014", "FEB 11, 2014", "JAN 24, 2014", "JAN 14, 2014", "JAN 14, 2014", "JAN 14, 2014", "JAN 14, 2014", "JAN 14, 2014", "JAN 14, 2014", "JAN 14, 2014", "JAN 14, 2014", "JAN 13, 2014", "JAN 13, 2014", "JAN 13, 2014", "JAN 10, 2014", "JAN 10, 2014", "JAN 9, 2014", "JAN 8, 2014", "JAN 3, 2014", "JAN 3, 2014", "JAN 6, 2014", "JAN 6, 2014", "JAN 6, 2014", "JAN 6, 2014", "JAN 3, 2014", "JAN 3, 2014", "JAN 3, 2014", "JAN 3, 2014", "JAN 6, 2014", "JAN 3, 2014", "JAN 3, 2014", "JAN 2, 2014", "JAN 2, 2014", "JAN 2, 2014", "JAN 2, 2014", "JAN 2, 2014", "JAN 3, 2014", "DEC 31, 2013", "DEC 30, 2013", "DEC 27, 2013", "DEC 27, 2013", "DEC 27, 2013", "DEC 27, 2013", "DEC 27, 2013", "DEC 30, 2013", "DEC 30, 2013", "DEC 30, 2013", "DEC 27, 2013", "DEC 26, 2013", "DEC 26, 2013", "DEC 26, 2013", "DEC 24, 2013", "DEC 27, 2013", "DEC 27, 2013", "DEC 27, 2013", "DEC 26, 2013", "DEC 26, 2013", "DEC 26, 2013", "DEC 26, 2013", "DEC 24, 2013", "DEC 24, 2013", "DEC 24, 2013", "DEC 24, 2013", "DEC 24, 2013", "DEC 24, 2013", "DEC 24, 2013", "DEC 24, 2013", "DEC 24, 2013", "DEC 24, 2013", "DEC 23, 2013", "DEC 23, 2013", "DEC 20, 2013", "DEC 20, 2013", "DEC 20, 2013", "DEC 20, 2013", "DEC 19, 2013", "DEC 20, 2013", "DEC 20, 2013", "DEC 19, 2013", "DEC 19, 2013", "DEC 19, 2013", "DEC 19, 2013", "DEC 18, 2013", "DEC 18, 2013", "DEC 19, 2013", "DEC 19, 2013", "DEC 19, 2013", "DEC 19, 2013", "DEC 19, 2013", "DEC 19, 2013", "DEC 18, 2013", "DEC 18, 2013", "DEC 18, 2013", "DEC 18, 2013", "DEC 17, 2013", "DEC 17, 2013", "DEC 17, 2013", "DEC 16, 2013", "DEC 16, 2013", "DEC 11, 2013", "DEC 16, 2013", "DEC 16, 2013", "DEC 9, 2013", "DEC 9, 2013", "DEC 9, 2013", "DEC 9, 2013", "DEC 6, 2013", "DEC 6, 2013", "DEC 10, 2013", "DEC 10, 2013", "DEC 9, 2013", "DEC 9, 2013", "DEC 9, 2013", "DEC 9, 2013", "DEC 6, 2013", "DEC 6, 2013", "DEC 10, 2013", "DEC 6, 2013", "DEC 6, 2013", "DEC 5, 2013", "DEC 5, 2013", "DEC 5, 2013", "DEC 5, 2013", "DEC 5, 2013", "DEC 6, 2013", "DEC 4, 2013", "DEC 4, 2013", "DEC 3, 2013", "DEC 3, 2013", "DEC 3, 2013", "DEC 3, 2013", "DEC 3, 2013", "DEC 4, 2013", "DEC 2, 2013", "DEC 2, 2013", "NOV 29, 2013", "NOV 29, 2013", "NOV 29, 2013", "NOV 29, 2013", "NOV 27, 2013", "DEC 2, 2013", "NOV 26, 2013", "NOV 26, 2013", "NOV 26, 2013", "NOV 25, 2013", "NOV 25, 2013", "NOV 22, 2013", "NOV 22, 2013", "NOV 27, 2013", "NOV 21, 2013", "NOV 21, 2013", "NOV 21, 2013", "NOV 21, 2013", "NOV 21, 2013", "NOV 20, 2013", "NOV 20, 2013", "NOV 20, 2013", "NOV 19, 2013", "NOV 19, 2013", "NOV 18, 2013", "NOV 14, 2013", "NOV 14, 2013", "NOV 14, 2013", "NOV 13, 2013", "NOV 15, 2013", "NOV 15, 2013", "NOV 14, 2013", "NOV 14, 2013", "NOV 14, 2013", "NOV 14, 2013", "NOV 14, 2013", "NOV 13, 2013", "NOV 13, 2013", "NOV 13, 2013", "NOV 13, 2013", "NOV 12, 2013", "NOV 5, 2013", "OCT 25, 2013", "OCT 7, 2013", "NOV 11, 2013", "OCT 7, 2013", "OCT 4, 2013", "OCT 4, 2013", "OCT 4, 2013", "OCT 3, 2013", "OCT 3, 2013", "OCT 3, 2013", "OCT 7, 2013", "OCT 7, 2013", "OCT 4, 2013", "OCT 4, 2013", "OCT 4, 2013", "OCT 3, 2013", "OCT 3, 2013", "OCT 3, 2013", "OCT 3, 2013", "OCT 2, 2013", "OCT 1, 2013", "OCT 1, 2013", "SEP 23, 2013", "SEP 20, 2013", "SEP 19, 2013", "SEP 19, 2013", "SEP 26, 2013", "SEP 25, 2013", "SEP 25, 2013", "SEP 24, 2013", "SEP 23, 2013", "SEP 20, 2013", "SEP 19, 2013", "SEP 19, 2013", "SEP 17, 2013", "SEP 11, 2013", "SEP 11, 2013", "SEP 11, 2013", "SEP 10, 2013", "SEP 10, 2013", "SEP 10, 2013", "SEP 12, 2013", "SEP 12, 2013", "SEP 11, 2013", "SEP 11, 2013", "SEP 11, 2013", "SEP 10, 2013", "SEP 10, 2013", "SEP 10, 2013", "SEP 12, 2013", "SEP 9, 2013", "SEP 6, 2013", "SEP 6, 2013", "SEP 6, 2013", "AUG 30, 2013", "AUG 30, 2013", "SEP 4, 2013", "SEP 4, 2013", "SEP 4, 2013", "SEP 3, 2013", "SEP 3, 2013", "SEP 3, 2013", "AUG 30, 2013", "AUG 30, 2013", "AUG 30, 2013", "AUG 21, 2013", "AUG 21, 2013", "AUG 20, 2013", "AUG 13, 2013", "AUG 12, 2013", "AUG 12, 2013", "AUG 9, 2013", "AUG 22, 2013", "AUG 21, 2013", "AUG 21, 2013", "AUG 20, 2013", "AUG 7, 2013", "AUG 7, 2013", "AUG 7, 2013", "AUG 6, 2013", "AUG 8, 2013", "AUG 8, 2013", "AUG 8, 2013", "AUG 7, 2013", "AUG 7, 2013", "AUG 7, 2013", "AUG 7, 2013", "AUG 6, 2013", "AUG 8, 2013", "AUG 5, 2013", "AUG 5, 2013", "AUG 2, 2013", "AUG 2, 2013", "AUG 1, 2013", "JUL 31, 2013", "JUL 31, 2013", "JUL 29, 2013", "JUL 29, 2013", "JUL 29, 2013", "JUL 26, 2013", "JUL 25, 2013", "JUL 25, 2013", "JUL 25, 2013", "JUL 26, 2013", "JUL 26, 2013", "JUL 25, 2013", "JUL 25, 2013", "JUL 25, 2013", "JUL 25, 2013", "JUL 25, 2013", "JUL 25, 2013", "JUL 25, 2013", "JUL 23, 2013", "JUL 23, 2013", "JUL 23, 2013", "JUL 22, 2013", "JUL 22, 2013", "JUL 22, 2013", "JUL 19, 2013", "JUL 23, 2013", "JUL 23, 2013", "JUL 23, 2013", "JUL 23, 2013", "JUL 22, 2013", "JUL 22, 2013", "JUL 22, 2013", "JUL 19, 2013", "JUL 23, 2013", "JUL 19, 2013", "JUL 11, 2013", "JUL 10, 2013", "JUL 9, 2013", "JUL 9, 2013", "JUL 9, 2013", "JUL 11, 2013", "JUL 11, 2013", "JUL 11, 2013", "JUL 11, 2013", "JUL 10, 2013", "JUL 9, 2013", "JUL 8, 2013", "JUL 5, 2013", "JUL 9, 2013", "JUL 9, 2013", "JUL 5, 2013", "JUL 3, 2013", "JUL 3, 2013", "JUL 2, 2013", "JUL 2, 2013", "JUL 2, 2013", "JUL 5, 2013", "JUL 5, 2013", "JUL 5, 2013", "JUL 3, 2013", "JUL 3, 2013", "JUL 2, 2013", "JUL 2, 2013", "JUN 27, 2013", "JUL 2, 2013", "JUN 27, 2013", "JUN 26, 2013", "JUN 26, 2013", "JUN 26, 2013", "JUN 26, 2013", "JUN 25, 2013", "JUN 25, 2013", "JUN 27, 2013", "JUN 27, 2013", "JUN 26, 2013", "JUN 26, 2013", "JUN 24, 2013", "JUN 24, 2013", "JUN 24, 2013", "JUN 25, 2013", "JUN 21, 2013", "JUN 21, 2013", "JUN 21, 2013", "JUN 21, 2013", "JUN 20, 2013", "JUN 20, 2013", "JUN 19, 2013", "JUN 24, 2013", "JUN 21, 2013", "JUN 21, 2013", "JUN 18, 2013", "JUN 18, 2013", "JUN 18, 2013", "JUN 18, 2013", "JUN 19, 2013", "JUN 18, 2013", "JUN 17, 2013", "JUN 17, 2013", "JUN 17, 2013", "JUN 17, 2013", "JUN 14, 2013", "JUN 13, 2013", "JUN 18, 2013", "JUN 13, 2013", "JUN 13, 2013", "JUN 11, 2013", "JUN 10, 2013", "JUN 10, 2013", "JUN 10, 2013", "JUN 10, 2013", "JUN 13, 2013", "JUN 13, 2013", "JUN 13, 2013", "JUN 11, 2013", "JUN 10, 2013", "JUN 10, 2013", "JUN 6, 2013", "JUN 5, 2013", "JUN 10, 2013", "JUN 10, 2013", "JUN 7, 2013", "JUN 7, 2013", "JUN 7, 2013", "JUN 6, 2013", "JUN 6, 2013", "JUN 5, 2013", "JUN 5, 2013", "JUN 4, 2013", "JUN 4, 2013", "MAY 31, 2013", "MAY 31, 2013", "MAY 31, 2013", "MAY 31, 2013", "JUN 3, 2013", "MAY 30, 2013", "MAY 30, 2013", "MAY 30, 2013", "MAY 29, 2013", "MAY 29, 2013", "MAY 28, 2013", "MAY 28, 2013", "MAY 30, 2013", "MAY 24, 2013", "MAY 24, 2013", "MAY 23, 2013", "MAY 23, 2013", "MAY 23, 2013", "MAY 23, 2013", "MAY 22, 2013", "MAY 28, 2013", "MAY 24, 2013", "MAY 22, 2013", "MAY 22, 2013", "MAY 22, 2013", "MAY 21, 2013", "MAY 20, 2013", "MAY 15, 2013", "MAY 22, 2013", "MAY 15, 2013", "MAY 15, 2013", "MAY 15, 2013", "MAY 14, 2013", "MAY 14, 2013", "MAY 13, 2013", "MAY 13, 2013", "MAY 15, 2013", "MAR 27, 2013", "MAR 5, 2013", "FEB 26, 2013", "JAN 14, 2013", "DEC 5, 2012", "NOV 9, 2012", "NOV 8, 2012", "MAY 13, 2013", "SEP 18, 2012", "SEP 13, 2012", "SEP 4, 2012", "AUG 7, 2012", "JUL 23, 2012", "JUN 18, 2012", "JUN 14, 2012", "OCT 22, 2012", "OCT 31, 2011", "OCT 18, 2011", "OCT 18, 2011", "AUG 31, 2011", "AUG 11, 2011", "AUG 2, 2011", "JUL 15, 2011", "APR 19, 2012", "FEB 24, 2011", "DEC 13, 2010", "NOV 18, 2010", "NOV 9, 2010", "OCT 11, 2010", "OCT 11, 2010", "OCT 5, 2010", "JUL 11, 2011", "JUN 15, 2010"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/biotech-stocks-facing-fda-decision-in-july-2020-2020-06-25", "https://www.nasdaq.com/articles/3-reasons-jazz-pharmaceuticals-is-a-hot-buy-right-now-2020-06-23", "https://www.nasdaq.com/articles/fda-nod-for-jazzs-drug-bysis-protective-2-trial-meets-goals-edsa-to-begin-covid-19-drug", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-boeing-chesapeake-energy-ideanomics-2020-06-08", "https://www.nasdaq.com/articles/2-top-healthcare-stocks-to-buy-right-now-2020-05-28", "https://www.nasdaq.com/articles/sum-up-the-pieces%3A-vv-could-be-worth-%24150-2020-05-11", "https://www.nasdaq.com/articles/why-jazz-pharmaceuticals-symphony-of-growth-is-about-to-end-2020-05-09", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-jazz-q1-2020-earnings-call-transcript-2020-05-06", "https://www.nasdaq.com/articles/biotech-stocks-facing-fda-decision-in-july-2020-2020-06-25", "https://www.nasdaq.com/articles/2-cheap-healthcare-stocks-to-buy-now-2020-05-03", "https://www.nasdaq.com/articles/can-this-small-cap-biotech-win-a-%241-billion-market-opportunity-for-narcolepsy-2020-04-28", "https://www.nasdaq.com/articles/why-avadel-pharmaceuticals-stock-is-crushing-it-today-2020-04-27", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-peter-lynch-4-19-2020-2020-04-19", "https://www.nasdaq.com/articles/analysts-anticipate-vv-will-reach-%24151-2020-04-09", "https://www.nasdaq.com/articles/gild-seeks-to-revoke-coveted-status-elox-pauses-trial-prqr-on-watch-2020-03-26", "https://www.nasdaq.com/articles/5-healthcare-stocks-that-havent-been-this-cheap-in-at-least-10-years-2020-03-25", "https://www.nasdaq.com/articles/why-jazz-pharmaceuticals-sang-off-key-in-q1-2020-05-06", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-is-now-oversold-jazz-2020-03-23", "https://www.nasdaq.com/articles/got-%245000-here-are-4-stocks-the-smartest-investors-are-buying-right-now-2020-03-18", "https://www.nasdaq.com/articles/1-cheap-biotech-stock-to-buy-2020-03-16", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-peter-lynch-3-15-2020-2020-03-15", "https://www.nasdaq.com/articles/look-under-the-hood%3A-vot-has-18-upside-2020-03-09", "https://www.nasdaq.com/articles/the-11-best-and-11-worst-stocks-of-the-11-year-bull-market-2020-03-09", "https://www.nasdaq.com/articles/6-quality-biotech-stocks-on-sale-now-2020-03-06", "https://www.nasdaq.com/articles/validea-benjamin-graham-strategy-daily-upgrade-report-3-24-2020-2020-03-24", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-jazz-q4-2019-earnings-call-transcript-2020-02-26", "https://www.nasdaq.com/articles/oversold-conditions-for-jazz-pharmaceuticals-jazz-2020-02-24", "https://www.nasdaq.com/articles/heres-why-avadel-pharmaceuticals-stock-jumped-higher-today-2020-02-21", "https://www.nasdaq.com/articles/validea-joel-greenblatt-strategy-daily-upgrade-report-2-21-2020-2020-02-21", "https://www.nasdaq.com/articles/jazz-makes-notable-cross-below-critical-moving-average-2020-02-20", "https://www.nasdaq.com/articles/bbi-awaits-data-in-q2-blph-breathes-easy-big-day-for-bxrx-tomorrow-2020-02-19", "https://www.nasdaq.com/articles/jazz-pharma%3A-fda-grants-priority-review-for-lurbinectedin-2020-02-17", "https://www.nasdaq.com/articles/stock-alert%3A-will-jazzs-downbeat-outlook-pull-down-the-stock-2020-02-26", "https://www.nasdaq.com/articles/could-this-cancer-drug-developers-stock-make-you-rich-2020-02-14", "https://www.nasdaq.com/articles/could-this-cancer-drug-developers-stock-make-you-rich-2020-02-14-0", "https://www.nasdaq.com/articles/3-top-value-stocks-youll-want-to-own-in-february-2020-02-05", "https://www.nasdaq.com/articles/first-week-of-jazz-september-18th-options-trading-2020-02-03", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-peter-lynch-1-19-2020-2020-01-19", "https://www.nasdaq.com/articles/2-stocks-that-are-absurdly-cheap-right-now-2020-01-17", "https://www.nasdaq.com/articles/interesting-jazz-put-and-call-options-for-february-21st-2020-01-10", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-peter-lynch-2-16-2020-2020-02-16", "https://www.nasdaq.com/articles/analysts-forecast-11-gains-ahead-for-the-holdings-of-pph-2020-01-06", "https://www.nasdaq.com/articles/pharmamar-and-jazz-pharma-sign-license-deal-for-lurbinectedin-in-u.s.-2019-12-19", "https://www.nasdaq.com/articles/3-top-healthcare-stocks-to-buy-right-now-2019-12-19", "https://www.nasdaq.com/articles/up-25-in-2-months-this-healthcare-stock-could-climb-even-higher-2019-12-18", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-peter-lynch-12-15-2019-2019-12-15", "https://www.nasdaq.com/articles/how-the-pieces-add-up%3A-pjp-targets-%2470-2019-12-02", "https://www.nasdaq.com/articles/why-has-jazz-pharmas-stock-rallied-nearly-20-in-a-month-2019-11-27", "https://www.nasdaq.com/articles/the-10-best-healthcare-stocks-of-the-decade-2020-01-07", "https://www.nasdaq.com/articles/analysts-forecast-11-gains-ahead-for-the-holdings-of-pph-2020-01-06", "https://www.nasdaq.com/articles/pharmamar-and-jazz-pharma-sign-license-deal-for-lurbinectedin-in-u.s.-2019-12-19", "https://www.nasdaq.com/articles/validea-joel-greenblatt-strategy-daily-upgrade-report-10-8-2019-2019-10-08", "https://www.nasdaq.com/articles/sum-up-the-parts%3A-fnx-could-be-worth-%2476-2019-09-30", "https://www.nasdaq.com/articles/jazz-pharma-presents-jzp-258-phase-3-study-data-at-world-sleep-2019-2019-09-26", "https://www.nasdaq.com/articles/5-garp-stocks-to-buy-today-2019-08-27", "https://www.nasdaq.com/articles/why-has-jazz-pharmas-stock-rallied-nearly-20-in-a-month-2019-11-27-0", "https://www.nasdaq.com/articles/jazz-crosses-above-key-moving-average-level-2019-08-19", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-sings-a-sweet-tune-in-q2-2019-08-07", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-jazz-q2-2019-earnings-call-transcript-2019-08-07", "https://www.nasdaq.com/articles/the-implied-analyst-12-month-target-for-osiz-2019-07-30", "https://www.nasdaq.com/articles/3-incredibly-cheap-healthcare-stocks-2019-07-14", "https://www.nasdaq.com/articles/interesting-jazz-put-and-call-options-for-august-16th-2019-06-27", "https://www.nasdaq.com/articles/analysts-expect-sciu-will-reach-%2436-2019-06-27", "https://www.nasdaq.com/articles/whats-next-for-sarepta-therapeutics-after-its-surprising-fda-rejection-2019-08-21", "https://www.nasdaq.com/articles/jazz-crosses-above-key-moving-average-level-2019-08-19", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-sings-a-sweet-tune-in-q2-2019-08-07", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-jazz-q2-2019-earnings-call-transcript-2019-08-07", "https://www.nasdaq.com/articles/first-week-jazz-may-17th-options-trading-2019-03-19", "https://www.nasdaq.com/articles/is-jazz-pharmaceuticals-jazz-a-good-value-investor-pick-2019-03-12", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-jazz-pharmaceuticals-lululemon-athletica-abiomed-and", "https://www.nasdaq.com/articles/health-care-sector-update-for-05-08-2019%3A-bhvnghdxjazzptla-2019-05-08", "https://www.nasdaq.com/articles/health-care-sector-update-for-05-08-2019%3A-ghdxjazzplta-2019-05-08", "https://www.nasdaq.com/articles/3-best-biotech-bargain-stocks-market-right-now-2019-03-05", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-jazz-surges%3A-stock-moves-7.9-higher-2019-02-28", "https://www.nasdaq.com/articles/jazz-pharma-jazz-q4-earnings-sales-beat-stock-up-8-2019-02-27", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-plc-jazz-q4-2018-earnings-conference-call-transcript-2019-02-27", "https://www.nasdaq.com/articles/earnings-reaction-history-jazz-pharmaceut-500-follow-through-indicator-46-sensitive-2019", "https://www.nasdaq.com/articles/after-hours-earnings-report-february-26-2019-eog-psa-panw-meli-myl-veev-csgp-jazz-masi-tol", "https://www.nasdaq.com/articles/10-top-stocks-10-year-bull-market-2019-03-10", "https://www.nasdaq.com/articles/factors-to-know-ahead-of-herbalifes-hlf-q4-earnings-2019-02-12", "https://www.nasdaq.com/articles/health-care-sector-update-02122019-jazzgildkmdaohi-2019-02-12", "https://www.nasdaq.com/articles/why-jazz-jazz-could-beat-earnings-estimates-again-2019-02-06", "https://www.nasdaq.com/articles/first-week-jazz-september-20th-options-trading-2019-01-28", "https://www.nasdaq.com/articles/5-biotech-stocks-could-face-ma-next-2019-01-10", "https://www.nasdaq.com/articles/3-bargain-stocks-you-can-buy-right-now-2019-01-06", "https://www.nasdaq.com/articles/jazz-inks-deal-with-codiak-to-develop-exosome-therapeutics-2019-01-04", "https://www.nasdaq.com/articles/mylan-myl-to-report-q4-earnings%3A-whats-in-the-offing-2019-02-20", "https://www.nasdaq.com/articles/factors-to-know-ahead-of-herbalifes-hlf-q4-earnings-2019-02-12", "https://www.nasdaq.com/articles/health-care-sector-update-02122019-jazzgildkmdaohi-2019-02-12", "https://www.nasdaq.com/articles/why-jazz-jazz-could-beat-earnings-estimates-again-2019-02-06", "https://www.nasdaq.com/articles/surprising-analyst-12-month-target-vlue-2018-12-17", "https://www.nasdaq.com/articles/jazz-jazz-increases-share-buyback-authorization-by-%24400m-2018-12-11", "https://www.nasdaq.com/articles/why-is-jazz-jazz-up-3-since-last-earnings-report-2018-12-06", "https://www.nasdaq.com/articles/3-cheapest-drug-stocks-you-can-buy-2019-2018-12-26", "https://www.nasdaq.com/articles/analysts-forecast-21-upside-jkh-2018-11-15", "https://www.nasdaq.com/articles/moving-average-crossover-alert%3A-jazz-pharmaceuticals-jazz-2018-11-13", "https://www.nasdaq.com/articles/health-care-sector-update-11092018-jazzacrxacetntra-2018-11-09", "https://www.nasdaq.com/articles/jazz-pharma-jazz-beats-on-q3-earnings-lowers-sales-view-2018-11-08", "https://www.nasdaq.com/articles/why-jazz-pharmaceuticals-plc-stock-slumping-today-2018-11-07", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-jazz-tops-q3-earnings-estimates-2018-11-06", "https://www.nasdaq.com/articles/earnings-reaction-history-jazz-pharmaceuticals-inc-333-follow-through-indicator-32", "https://www.nasdaq.com/articles/health-care-sector-update-11292018-alkseyptjazz-2018-11-29", "https://www.nasdaq.com/articles/bullish-two-hundred-day-moving-average-cross-jazz-2018-11-01", "https://www.nasdaq.com/articles/first-week-jazz-november-16th-options-trading-2018-10-15", "https://www.nasdaq.com/articles/5-low-price-to-book-stocks-to-buy-in-a-volatile-market-2018-10-12", "https://www.nasdaq.com/articles/jazz-crosses-below-key-moving-average-level-2018-10-11", "https://www.nasdaq.com/articles/jazz-or-zts%3A-which-is-the-better-value-stock-right-now-2018-10-10", "https://www.nasdaq.com/articles/is-jazz-pharmaceuticals-a-great-stock-for-value-investors-2018-09-20", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-now-oversold-jazz-2018-09-17", "https://www.nasdaq.com/articles/after-hours-earnings-report-november-6-2018-pxd-dxc-paa-dvn-gddy-jkhy-fang-dxcm-lnt-jazz", "https://www.nasdaq.com/articles/bullish-two-hundred-day-moving-average-cross-jazz-2018-11-01", "https://www.nasdaq.com/articles/first-week-jazz-november-16th-options-trading-2018-10-15", "https://www.nasdaq.com/articles/jazzs-jazz-leukemia-drug-vyxeos-gets-approval-in-europe-2018-08-27", "https://www.nasdaq.com/articles/5-low-cost-biotech-stocks-with-high-levels-of-growth-2018-08-21", "https://www.nasdaq.com/articles/8-undervalued-biotech-stocks-to-watch-2018-08-20", "https://www.nasdaq.com/articles/analysts-see-10-upside-sciu-2018-08-14", "https://www.nasdaq.com/articles/jazz-pharmas-jazz-stock-down-despite-q2-earnings-beat-2018-08-08", "https://www.nasdaq.com/articles/3-biotech-stocks-analysts-say-are-market-winners-2018-09-13", "https://www.nasdaq.com/articles/why-is-jazz-jazz-down-2.4-since-last-earnings-report-2018-09-06", "https://www.nasdaq.com/articles/jazz-december-2019-options-begin-trading-2018-08-28", "https://www.nasdaq.com/articles/jazzs-jazz-leukemia-drug-vyxeos-gets-approval-in-europe-2018-08-27", "https://www.nasdaq.com/articles/5-low-cost-biotech-stocks-with-high-levels-of-growth-2018-08-21", "https://www.nasdaq.com/articles/8-undervalued-biotech-stocks-to-watch-2018-08-20", "https://www.nasdaq.com/articles/zillow-group-zg-to-report-q2-earnings%3A-is-a-beat-in-store-2018-08-02", "https://www.nasdaq.com/articles/ansys-anss-to-report-q2-earnings%3A-whats-in-the-offing-2018-08-02", "https://www.nasdaq.com/articles/7-biotech-stocks-big-upcoming-catalysts-2018-08-08", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity-jazz-car-axdx-2018-08-07", "https://www.nasdaq.com/articles/after-hours-earnings-report-august-7-2018-dis-pxd-dxc-clr-paa-hst-snap-jazz-iff-alb-xec-pe", "https://www.nasdaq.com/articles/is-a-beat-in-store-for-endocyte-ecyt-this-earnings-season-2018-07-27", "https://www.nasdaq.com/articles/5-low-price-to-book-stocks-worth-buying-in-july-2018-07-09", "https://www.nasdaq.com/articles/5-low-price-book-stocks-worth-buying-july-2018-07-09-0", "https://www.nasdaq.com/articles/aclaris-stock-up-on-jak-inhibitors-encouraging-activity-2018-07-06", "https://www.nasdaq.com/articles/dermira-derm-gains-5-in-a-week-post-qbrexa-approval-2018-07-06", "https://www.nasdaq.com/articles/whats-in-store-for-catalyst-cprx-this-earnings-season-2018-08-01", "https://www.nasdaq.com/articles/jazz-sells-pain-drug-prialts-rights-to-tersera-therapeutics-2018-07-02", "https://www.nasdaq.com/articles/5-stocks-near-52-week-high%3A-is-more-upside-in-the-cards-2018-06-29", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-snda-for-xyrem-gets-priority-review-2018-06-28", "https://www.nasdaq.com/articles/5-low-beta-stocks-buy-trade-conflict-intensifies-2018-06-19", "https://www.nasdaq.com/articles/small-drugmakers-edging-out-bigshots-7-stocks-buy-2018-06-19", "https://www.nasdaq.com/articles/zacks.com-highlights%3A-jazz-pharmaceuticals-baxter-international-boise-cascade-insight", "https://www.nasdaq.com/articles/5-stocks-near-52-week-high-with-more-room-to-run-2018-06-15", "https://www.nasdaq.com/articles/10-underappreciated-biotech-stocks-buy-2018-07-03", "https://www.nasdaq.com/articles/jazz-sells-pain-drug-prialts-rights-to-tersera-therapeutics-2018-07-02", "https://www.nasdaq.com/articles/5-stocks-near-52-week-high%3A-is-more-upside-in-the-cards-2018-06-29", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-snda-for-xyrem-gets-priority-review-2018-06-28", "https://www.nasdaq.com/articles/5-low-beta-stocks-buy-trade-conflict-intensifies-2018-06-19", "https://www.nasdaq.com/articles/small-drugmakers-edging-out-bigshots-7-stocks-buy-2018-06-19", "https://www.nasdaq.com/articles/zacks.com-highlights%3A-jazz-pharmaceuticals-baxter-international-boise-cascade-insight", "https://www.nasdaq.com/articles/5-stocks-near-52-week-high-with-more-room-to-run-2018-06-15", "https://www.nasdaq.com/articles/10-underappreciated-biotech-stocks-buy-2018-07-03", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-jazz-up-16.9-since-earnings-report%3A-can-it-continue-2018-06-07", "https://www.nasdaq.com/articles/3-biotechs-fdas-naughty-list-should-be-investors-buy-lists-2018-05-22", "https://www.nasdaq.com/articles/look-under-hood-qus-has-10-upside-2018-05-16", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-jazz-q1-earnings-sales-top-estimates-2018-05-09", "https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-may-2018-05-09", "https://www.nasdaq.com/articles/after-hours-earnings-report-february-27-2018-eog-esrx-wday-sq-alb-fmx-lyv-jazz-midd-veev", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-jazz-q4-earnings%3A-what-to-expect-2018-02-21", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-jazz-q1-earnings%3A-whats-in-store-2018-05-02", "https://www.nasdaq.com/articles/sizes-underlying-holdings-could-mean-12-gain-potential-2018-04-12", "https://www.nasdaq.com/articles/first-week-may-18th-options-trading-jazz-pharmaceuticals-jazz-2018-04-02", "https://www.nasdaq.com/articles/should-value-investors-pick-jazz-pharmaceuticals-jazz-stock-2018-03-16", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-jazz-shares-cross-above-200-dma-2018-03-08", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-jazz-q4-earnings-miss-sales-up-y-y-2018-02-28", "https://www.nasdaq.com/articles/after-hours-earnings-report-february-27-2018-eog-esrx-wday-sq-alb-fmx-lyv-jazz-midd-veev", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-jazz-q4-earnings%3A-what-to-expect-2018-02-21", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-jazz-q1-earnings%3A-whats-in-store-2018-05-02", "https://www.nasdaq.com/articles/implied-dwpp-analyst-target-price-32-2018-02-07", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-ihe-pfe-prgo-jazz-2018-01-26", "https://www.nasdaq.com/articles/concert-pharmaceuticals-plunges-on-patent-petition-setback-2018-01-15", "https://www.nasdaq.com/articles/5-biotech-stocks-could-be-bought-out-2018-2018-01-14", "https://www.nasdaq.com/articles/immunogen-starts-phase-i-study-on-leukemia-candidate-imgn632-2018-01-05", "https://www.nasdaq.com/articles/jazz-submits-nda-to-fda-for-jzp-110-to-cure-sleep-disorder-2017-12-22", "https://www.nasdaq.com/articles/health-care-sector-update-12212017-jazzaezsjnjacstacstv-2017-12-21", "https://www.nasdaq.com/articles/why-immunogen-jumped-higher-today-2018-02-12", "https://www.nasdaq.com/articles/health-care-sector-update-12192017-cgixtmopfnxjazzthc-2017-12-19", "https://www.nasdaq.com/articles/immunogen-inc-moves-forward-2017-11-09", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-jazz-q3-earnings-top-2017-view-cut-2017-11-08", "https://www.nasdaq.com/articles/after-hours-earnings-report-november-7-2017-mar-etp-ete-clr-agu-alny-xec-ttwo-dva-jkhy", "https://www.nasdaq.com/articles/asymmetry-capital-management-lp-buys-insmed-inc-ionis-pharmaceuticals-inc-hms-holdings", "https://www.nasdaq.com/articles/immunogen-running-out-steam-or-taking-breather-2017-09-16", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-enters-oversold-territory-jazz-2017-10-27", "https://www.nasdaq.com/articles/immunogen-to-push-leukemia-candidate-into-phase-i-trial-2017-10-17", "https://www.nasdaq.com/articles/notable-two-hundred-day-moving-average-cross-jazz-2017-10-10", "https://www.nasdaq.com/articles/genocea-biosciences-gnca-jumps%3A-stock-rises-24.8-2017-10-06", "https://www.nasdaq.com/articles/rigel-pharmaceuticals-rigl-in-focus%3A-stock-moves-12.1-higher-2017-10-05", "https://www.nasdaq.com/articles/synergy-pharmaceuticals-sgyp-surges%3A-stock-moves-12.1-higher-2017-10-03", "https://www.nasdaq.com/articles/immunogen-imgn-in-focus%3A-stock-moves-17.3-higher-2017-08-30", "https://www.nasdaq.com/articles/5-excellent-value-stocks-based-on-low-peg-ratio-2017-08-30", "https://www.nasdaq.com/articles/3-pharma-biotech-sector-bargains-for-a-healthy-portfolio-2017-09-13", "https://www.nasdaq.com/articles/5-key-things-you-should-watch-jazz-pharmaceuticals-2017-09-07", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-oreilly-automotive-and-tesla-highlighted-as-zacks-bull-and-bear-of", "https://www.nasdaq.com/articles/bull-day-jazz-pharmaceuticals-jazz-2017-09-05", "https://www.nasdaq.com/articles/zacks.com-featured-highlights-include-lantheus-holdings-jazz-pharmaceuticals-gray", "https://www.nasdaq.com/articles/immunogen-inks-deal-with-jazz-pharma-to-develop-adc-molecule-2017-08-30", "https://www.nasdaq.com/articles/immunogen-imgn-in-focus%3A-stock-moves-17.3-higher-2017-08-30", "https://www.nasdaq.com/articles/5-excellent-value-stocks-based-on-low-peg-ratio-2017-08-30", "https://www.nasdaq.com/articles/3-pharma-biotech-sector-bargains-for-a-healthy-portfolio-2017-09-13", "https://www.nasdaq.com/articles/midday-update-wall-street-recovers-overnight-sell-supports-remain-intact-2017-08-29", "https://www.nasdaq.com/articles/us-stock-futures-roiled-north-korean-missile-test-over-japan-2017-08-29", "https://www.nasdaq.com/articles/health-care-sector-update-08292017-jnj-pfe-abt-mrk-amgn-imgn-etrm-2017-08-29", "https://www.nasdaq.com/articles/why-movado-group-catalent-and-immunogen-jumped-today-2017-08-29", "https://www.nasdaq.com/articles/health-care-sector-update-08292017-imgnjazzjunoacor-2017-08-29", "https://www.nasdaq.com/articles/why-immunogen-inc-jumped-higher-today-2017-08-29", "https://www.nasdaq.com/articles/3-top-stocks-your-ira-august-2017-08-10", "https://www.nasdaq.com/articles/analysts-expect-11-upside-holdings-iyh-2017-08-25", "https://www.nasdaq.com/articles/ironwood-pharmas-combination-gout-drug-gets-fda-approval-2017-08-22", "https://www.nasdaq.com/articles/rally-set-resume-buy-these-5-value-picks-dip-2017-08-22", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-arm-announces-%24500m-senior-notes-offer-2017-08-18", "https://www.nasdaq.com/articles/endo-international-endp-jumps%3A-stock-rises-6.9-2017-08-17", "https://www.nasdaq.com/articles/jounce-therapeutics-jnce-jumps%3A-stock-moves-7.4-higher-2017-08-17", "https://www.nasdaq.com/articles/rk-capital-management-llc-buys-electronics-imaging-inc-douglas-dynamics-inc-kbr-inc-2017", "https://www.nasdaq.com/articles/ihe-zts-myl-jazz-large-outflows-detected-etf-2017-06-16", "https://www.nasdaq.com/articles/oversold-conditions-jazz-pharmaceuticals-jazz-2017-08-09", "https://www.nasdaq.com/articles/jazz-pharma-jazz-q2-earnings-revenues-miss-view-intact-2017-08-09", "https://www.nasdaq.com/articles/after-hours-earnings-report-august-8-2017-dis-pcln-mnst-etp-ete-fnv-clr-andv-iff-jazz-xec", "https://www.nasdaq.com/articles/can-jazz-pharma-jazz-spring-a-surprise-in-q2-earnings-2017-08-03", "https://www.nasdaq.com/articles/sum-pieces-pph-could-be-worth-65-2017-07-25", "https://www.nasdaq.com/articles/aveos-kidney-cancer-candidate-gets-chmp-recommendation-2017-06-27", "https://www.nasdaq.com/articles/3-reasons-jazz-pharmaceuticals-stock-could-fall-2017-06-18", "https://www.nasdaq.com/articles/3-mid-cap-stocks-big-cap-potential-2017-06-15", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-jazz-misses-q1-earnings-sales-2017-05-10", "https://www.nasdaq.com/articles/earnings-reaction-history-jazz-pharmaceuticals-inc-250-follow-through-indicator-29", "https://www.nasdaq.com/articles/after-hours-earnings-report-may-9-2017-dis-pcln-nvda-ea-slf-mchp-fnv-reg-jazz-dox-zayo", "https://www.nasdaq.com/articles/jazz-pharma-jazz-q1-earnings%3A-stock-likely-to-disappoint-2017-05-03", "https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-now-2017-04-29", "https://www.nasdaq.com/articles/analysts-predict-11-gains-ahead-holdings-iyh-2017-04-12", "https://www.nasdaq.com/articles/spdr-sp-pharmaceuticals-etf-experiences-big-outflow-2017-04-10", "https://www.nasdaq.com/articles/4-cheapest-biotech-stocks-world-2017-05-11", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-jazz-misses-q1-earnings-sales-2017-05-10", "https://www.nasdaq.com/articles/health-care-sector-update-04062017-jazzaktxnvgn-2017-04-06", "https://www.nasdaq.com/articles/bridges-investment-management-inc-buys-ishares-core-sp-small-cap-vanguard-ftse-all-world", "https://www.nasdaq.com/articles/jazz-pharma-completes-nda-filing-for-leukemia-drug-to-fda-2017-04-04", "https://www.nasdaq.com/articles/jazz-pharma-jazz-up-7.6-since-earnings-report%3A-can-it-continue-2017-03-31", "https://www.nasdaq.com/articles/why-youre-smart-buy-jazz-pharmaceuticals-plc-2017-03-24", "https://www.nasdaq.com/articles/should-you-drop-what-youre-doing-and-buy-jazz-pharmaceuticals-stock-2017-04-07", "https://www.nasdaq.com/articles/mondays-etf-unusual-volume-urth-2017-03-20", "https://www.nasdaq.com/articles/jazz-initiates-phase-iii-study-for-narcolepsy-candidate-2017-03-16", "https://www.nasdaq.com/articles/jazz-pharma-jazz-q4-earnings-beat-sales-miss-estimates-2017-03-01", "https://www.nasdaq.com/articles/after-hours-earnings-report-february-28-2017-crm-rost-panw-uhs-tsro-jazz-ar-dxcm-epr-logm", "https://www.nasdaq.com/articles/earnings-reaction-history-jazz-pharmaceuticals-inc-222-follow-through-indicator-29", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-ihe-myl-jazz-prgo-2017-02-24", "https://www.nasdaq.com/articles/jazz-pharma-jazz-q4-earnings%3A-is-a-surprise-in-store-2017-02-23", "https://www.nasdaq.com/articles/jazz-sleep-disorder-drug-positive-in-phase-iii-studies-2017-03-21", "https://www.nasdaq.com/articles/bullish-two-hundred-day-moving-average-cross-jazz-2017-02-09", "https://www.nasdaq.com/articles/5-drug-stocks-poised-beat-earnings-estimates-q4-2017-02-09", "https://www.nasdaq.com/articles/why-jazz-pharmaceuticals-plcs-shareholders-didnt-sleep-12-gain-january-2017-02-03", "https://www.nasdaq.com/articles/these-3-biotech-stocks-are-ridiculously-cheap-2017-02-01", "https://www.nasdaq.com/articles/top-healthcare-stocks-buy-2017-2017-01-31", "https://www.nasdaq.com/articles/xph-jazz-lly-hznp-large-outflows-detected-etf-2017-01-30", "https://www.nasdaq.com/articles/math-shows-iyh-can-go-169-2017-01-30", "https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-sale-2017-02-13", "https://www.nasdaq.com/articles/can-jazz-pharmaceuticals-be-a-top-choice-for-value-investors-2017-01-20", "https://www.nasdaq.com/articles/can-jazz-pharmaceuticals-be-a-top-choice-for-value-investors-2017-01-19", "https://www.nasdaq.com/articles/5-biotech-stocks-youll-want-watch-1st-quarter-2017-01-18", "https://www.nasdaq.com/articles/jazz-begins-phase-iii-study-for-label-expansion-of-defitelio-2017-01-18", "https://www.nasdaq.com/articles/start-new-year-right-3-best-biotech-stocks-2017-01-08", "https://www.nasdaq.com/articles/heres-why-jazz-pharmaceuticals-plc-fell-out-tune-and-lost-22-2016-2017-01-05", "https://www.nasdaq.com/articles/4-top-stocks-sale-winter-2017-01-02", "https://www.nasdaq.com/articles/3-most-unbelievably-undervalued-biotech-stocks-2017-01-27", "https://www.nasdaq.com/articles/3-top-healthcare-stocks-youve-been-overlooking-2016-12-18", "https://www.nasdaq.com/articles/jazz-completes-patient-enrollment-in-jzp-110-narcolepsy-trial-2016-11-29", "https://www.nasdaq.com/articles/jazz-pharma-jazz-q3-earnings-top-sales-lag-estimates-2016-11-09", "https://www.nasdaq.com/articles/5-sectors-poised-benefit-donald-trumps-victory-2016-11-09", "https://www.nasdaq.com/articles/after-hours-earnings-report-november-8-2016-cxo-dox-trip-zayo-ash-jazz-vsat-cpa-cvg-psec", "https://www.nasdaq.com/articles/pricing-concerns-push-jazz-pharmaceuticals-plc-down-10-october-2016-11-02", "https://www.nasdaq.com/articles/jazz-pharma-jazz-q3-earnings%3A-a-disappointment-in-store-2016-11-01", "https://www.nasdaq.com/articles/first-week-february-2017-options-trading-jazz-pharmaceuticals-jazz-2016-12-27", "https://www.nasdaq.com/articles/3-top-healthcare-stocks-youve-been-overlooking-2016-12-18", "https://www.nasdaq.com/articles/jazz-pharma-closes-enrollment-in-osa-drug-phase-iii-trial-2016-09-28", "https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-sale-2016-09-26", "https://www.nasdaq.com/articles/peek-under-hood-xph-has-25-upside-2016-09-23", "https://www.nasdaq.com/articles/cheapest-stocks-biotech-2016-09-23", "https://www.nasdaq.com/articles/3-mid-cap-healthcare-stocks-you-can-buy-right-now-2016-09-10", "https://www.nasdaq.com/articles/weakness-seen-in-jazz-pharmaceuticals-jazz-estimates%3A-should-you-stay-away-2016-08-29", "https://www.nasdaq.com/articles/3-healthcare-stocks-are-looking-cheap-2016-10-20", "https://www.nasdaq.com/articles/4-top-biotech-stocks-can-be-purchased-cheap-summer-2016-08-16", "https://www.nasdaq.com/articles/jazz-jazz-q2-earnings-yy-lowers-earnings-outlook-2016-08-10", "https://www.nasdaq.com/articles/earnings-reaction-history-jazz-pharmaceuticals-inc-111-follow-through-indicator-25", "https://www.nasdaq.com/articles/after-hours-earnings-report-august-9-2016-dis-myl-mdvn-jazz-vsat-taho-xon-dplo-pcty-fltx", "https://www.nasdaq.com/articles/jazz-jazz-q2-earnings-will-stock-disappoint-2016-08-05", "https://www.nasdaq.com/articles/could-be-next-big-pharma-buyout-2016-07-18", "https://www.nasdaq.com/articles/forget-me-too-cancer-drugs-these-breakthroughs-are-where-you-want-invest-2016-07-17", "https://www.nasdaq.com/articles/pphs-holdings-imply-16-gain-potential-2016-08-22", "https://www.nasdaq.com/articles/why-celator-pharmaceuticals-1610-2016-2016-06-27", "https://www.nasdaq.com/articles/interesting-jazz-put-and-call-options-august-5th-2016-06-23", "https://www.nasdaq.com/articles/first-week-august-19th-options-trading-jazz-pharmaceuticals-jazz-2016-06-21", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-offers-hal-study-data-on-jzp-110-2016-06-15", "https://www.nasdaq.com/articles/4-cancer-drug-developers-you-need-have-your-radar-year-2016-06-15", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-xph-rlyp-akrx-jazz-2016-06-14", "https://www.nasdaq.com/articles/sum-parts-pxmg-could-be-worth-34-2016-06-14", "https://www.nasdaq.com/articles/jazz-august-26th-options-begin-trading-2016-07-07", "https://www.nasdaq.com/articles/why-celator-pharmaceuticals-1610-2016-2016-06-27", "https://www.nasdaq.com/articles/interesting-jazz-put-and-call-options-august-5th-2016-06-23", "https://www.nasdaq.com/articles/first-week-august-19th-options-trading-jazz-pharmaceuticals-jazz-2016-06-21", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-offers-hal-study-data-on-jzp-110-2016-06-15", "https://www.nasdaq.com/articles/4-cancer-drug-developers-you-need-have-your-radar-year-2016-06-15", "https://www.nasdaq.com/articles/why-celator-pharmaceuticals-shares-are-skyrocketing-today-2016-05-31", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-edge-higher-medtronic-earnings-top-views-2016-05-31", "https://www.nasdaq.com/articles/3-cheap-biotech-stocks-you-can-buy-now-2016-06-06", "https://www.nasdaq.com/articles/why-celator-pharmaceuticals-shares-skyrocketed-100-may-2016-06-04", "https://www.nasdaq.com/articles/company-news-for-june-01-2016-2016-06-01", "https://www.nasdaq.com/articles/midday-update-stocks-turn-defensive-after-digesting-mixed-economic-data-2016-05-31", "https://www.nasdaq.com/articles/mid-day-market-update-dow-falls-over-50-points-celator-pharmaceuticals-shares-jump-after", "https://www.nasdaq.com/articles/70-excessive-premium-celator-pharmaceuticals-inc-cpxx-jazz-2016-05-31", "https://www.nasdaq.com/articles/why-celator-pharmaceuticals-shares-are-skyrocketing-today-2016-05-31", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-edge-higher-medtronic-earnings-top-views-2016-05-31", "https://www.nasdaq.com/articles/3-cheap-biotech-stocks-you-can-buy-now-2016-06-06", "https://www.nasdaq.com/articles/after-hours-earnings-report-may-10-2016-dis-ea-slf-jazz-alb-kgc-nuan-ypf-xon-psec-fosl", "https://www.nasdaq.com/articles/drug-stocks-reporting-on-may-10%3A-xon-aria-cprx-more-2016-05-09", "https://www.nasdaq.com/articles/is-a-surprise-coming-for-jazz-pharmaceuticals-jazz-this-earnings-season-2016-05-09", "https://www.nasdaq.com/articles/whats-in-the-cards-for-catalyst-cprx-in-q1-earnings-2016-05-06", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-breaks-below-200-day-moving-average-notable-jazz-2016-05-06", "https://www.nasdaq.com/articles/ariad-aria-report-q1-earnings-will-stock-surprise-2016-05-06", "https://www.nasdaq.com/articles/allergan-agn-q1-earnings-will-stock-disappoint-2016-05-06", "https://www.nasdaq.com/articles/earnings-reaction-history-jazz-pharmaceuticals-inc-111-follow-through-indicator-27", "https://www.nasdaq.com/articles/jazz-jazz-q1-earnings%3A-a-beat-in-the-cards-for-the-stock-2016-05-06", "https://www.nasdaq.com/articles/teva-teva-q1-earnings-will-stock-deliver-surprise-2016-05-05", "https://www.nasdaq.com/articles/intrexon-xon%3A-stock-likely-to-beat-estimates-in-q1-earnings-2016-05-05", "https://www.nasdaq.com/articles/will-biodelivery-bdsi-disappoint-estimates-in-q1-earnings-2016-05-05", "https://www.nasdaq.com/articles/whats-in-the-cards-for-synta-snta-this-earnings-season-2016-05-05", "https://www.nasdaq.com/articles/inovio-ino%3A-whats-in-store-for-the-stock-in-q1-earnings-2016-05-04", "https://www.nasdaq.com/articles/kite-kite-report-q1-earnings-will-stock-disappoint-2016-05-04", "https://www.nasdaq.com/articles/immune-design-imdz-q1-earnings%3A-what-awaits-the-stock-2016-05-06", "https://www.nasdaq.com/articles/juno-juno-q1-earnings-whats-store-stock-2016-05-04", "https://www.nasdaq.com/articles/arena-arna-q1-earnings-whats-store-stock-2016-05-04", "https://www.nasdaq.com/articles/what-awaits-puma-biotechnology-pbyi-in-q1-earnings-2016-05-04", "https://www.nasdaq.com/articles/intercept-icpt%3A-stock-likely-to-disappoint-in-q1-earnings-2016-05-03", "https://www.nasdaq.com/articles/repros-rprx-q1-earnings-whats-store-stock-2016-05-03", "https://www.nasdaq.com/articles/geron-gern-q1-earnings-whats-store-stock-2016-05-03", "https://www.nasdaq.com/articles/conatus-cnat%3A-can-the-stock-surprise-in-q1-earnings-2016-05-03", "https://www.nasdaq.com/articles/whats-in-store-for-horizon-hznp-this-earnings-season-2016-05-04", "https://www.nasdaq.com/articles/juno-juno-q1-earnings-whats-store-stock-2016-05-04", "https://www.nasdaq.com/articles/endo-endp-q1-earnings%3A-whats-in-store-for-the-stock-2016-05-02", "https://www.nasdaq.com/articles/zoetis-zts%3A-stock-likely-to-beat-on-earnings-in-q1-again-2016-05-02", "https://www.nasdaq.com/articles/amerisourcebergen-abc-q2-earnings%3A-stock-to-surprise-2016-05-02", "https://www.nasdaq.com/articles/exelixis-exel%3A-whats-ahead-for-the-stock-in-q1-earnings-2016-05-02", "https://www.nasdaq.com/articles/endocyte-ecyt%3A-what-awaits-the-stock-in-q1-earnings-2016-05-02", "https://www.nasdaq.com/articles/whats-up-at-gw-pharmaceuticals-gwph-in-q2-earnings-2016-05-03", "https://www.nasdaq.com/articles/whats-in-store-for-agios-agio-this-earnings-season-2016-05-03", "https://www.nasdaq.com/articles/heres-why-jazz-pharmaceuticals-plc-was-receiving-end-15-boost-april-2016-05-03", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-breaks-above-200-day-moving-average-bullish-jazz-2016-04-13", "https://www.nasdaq.com/articles/jazzs-hepatic-vod-drug-defitelio-gains-fda-nod-shares-up-2016-03-31", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-syna-jazz-mxim-2016-03-30", "https://www.nasdaq.com/articles/implied-analyst-12-month-target-eusa-2016-03-10", "https://www.nasdaq.com/articles/mckesson-mck-q4-earnings%3A-stock-likely-to-disappoint-2016-05-02", "https://www.nasdaq.com/articles/most-important-fda-decision-were-watching-quarter-2016-03-07", "https://www.nasdaq.com/articles/commit-purchase-jazz-pharmaceuticals-80-earn-65-annualized-using-options-2016-03-01", "https://www.nasdaq.com/articles/jazz-tops-q4-earnings-revenues-up-y-y-gives-2016-view-2016-02-24", "https://www.nasdaq.com/articles/5-minute-guide-jazz-pharmaceuticals-plc-2016-02-23", "https://www.nasdaq.com/articles/earnings-reaction-history-jazz-pharmaceuticals-inc-200-follow-through-indicator-32", "https://www.nasdaq.com/articles/after-hours-earnings-report-february-23-2016-eix-vrsk-exr-jazz-y-fslr-wtr-dxcm-cprt-car", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-enters-oversold-territory-jazz-2016-02-11", "https://www.nasdaq.com/articles/3-reasons-jazz-pharmaceuticals-stock-could-rise-2016-2016-03-08", "https://www.nasdaq.com/articles/most-important-fda-decision-were-watching-quarter-2016-03-07", "https://www.nasdaq.com/articles/commit-purchase-jazz-pharmaceuticals-80-earn-65-annualized-using-options-2016-03-01", "https://www.nasdaq.com/articles/jazz-tops-q4-earnings-revenues-up-y-y-gives-2016-view-2016-02-24", "https://www.nasdaq.com/articles/5-minute-guide-jazz-pharmaceuticals-plc-2016-02-23", "https://www.nasdaq.com/articles/jazzs-q3-earnings-revenues-grow-y-y-trims-2015-outlook-2015-11-11", "https://www.nasdaq.com/articles/earnings-reaction-history-jazz-pharmaceuticals-inc-222-follow-through-indicator-33", "https://www.nasdaq.com/articles/ignore-regeneron-pharmaceuticals-inc-here-are-3-better-buys-right-now-2016-02-02", "https://www.nasdaq.com/articles/jazzs-phase-iii-data-on-defibrotide-published-in-ash-journal-2016-02-02", "https://www.nasdaq.com/articles/why-flamel-technologics-sa-tumbled-15-today-2016-01-08", "https://www.nasdaq.com/articles/3-companies-could-become-tax-inversion-targets-2015-11-30", "https://www.nasdaq.com/articles/these-biotech-stocks-may-start-paying-dividends-2016-2015-11-16", "https://www.nasdaq.com/articles/3-great-stocks-sale-2015-11-15", "https://www.nasdaq.com/articles/jazzs-defibrotide-under-fda-priority-review-shares-up-2015-10-01", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-jazz-crumbles%3A-stock-falls-by-7.7-2015-09-29", "https://www.nasdaq.com/articles/after-hours-earnings-report-november-9-2015-iff-jazz-leaf-ugi-lgf-opk-xon-rax-rare-apu", "https://www.nasdaq.com/articles/3-stocks-buy-now-biotech-2015-11-02", "https://www.nasdaq.com/articles/better-buy-now-medivation-inc-vs-jazz-pharmaceuticals-2015-10-24", "https://www.nasdaq.com/articles/first-week-jazz-june-2016-options-trading-2015-10-21", "https://www.nasdaq.com/articles/3-value-stocks-near-52-week-lows-worth-buying-2015-10-14", "https://www.nasdaq.com/articles/health-care-sector-update-10092015-jazz-lxrx-ipci-2015-10-09", "https://www.nasdaq.com/articles/jazzs-defibrotide-under-fda-priority-review-shares-up-2015-10-01", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-beats-earnings-misses-revenues-stocks-news-2015-08-05", "https://www.nasdaq.com/articles/3-mid-cap-biotechs-were-excited-about-2015-09-25", "https://www.nasdaq.com/articles/ewg-dwaq-big-etf-inflows-2015-07-28", "https://www.nasdaq.com/articles/wakefulness-drug-xyrem-keeps-jazz-pharmaceuticals-2015-07-28", "https://www.nasdaq.com/articles/commit-buy-jazz-pharmaceuticals-115-earn-68-using-options-2015-07-08", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-jazz-shares-cross-below-200-dma-2015-06-29", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-sleep-disorder-drug-enters-phase-iii-analyst-blog-2015-06-09", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-larger-sp-500-component-coca-cola-enterprises-2015-05-28", "https://www.nasdaq.com/articles/quicklogic-venture-capital-style-opportunity-public-market-investors-2015-05-12", "https://www.nasdaq.com/articles/winning-biotech-stock-looks-buy-2015-07-29", "https://www.nasdaq.com/articles/ewg-dwaq-big-etf-inflows-2015-07-28", "https://www.nasdaq.com/articles/wakefulness-drug-xyrem-keeps-jazz-pharmaceuticals-2015-07-28", "https://www.nasdaq.com/articles/commit-buy-jazz-pharmaceuticals-115-earn-68-using-options-2015-07-08", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-jazz-shares-cross-below-200-dma-2015-06-29", "https://www.nasdaq.com/articles/big-pharma-comes-under-attack-new-hedge-fund-strategy-2015-04-26", "https://www.nasdaq.com/articles/new-hedge-fund-strategy-just-might-be-crazy-enough-work-2015-04-19", "https://www.nasdaq.com/articles/will-hedge-fund-manager-bring-down-your-biotech-stocks-2015-04-19", "https://www.nasdaq.com/articles/why-shares-flamel-technologies-sa-bolted-higher-today-2015-05-08", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-misses-on-q1-earnings-affirms-view-analyst-blog-2015-05-08", "https://www.nasdaq.com/articles/earnings-reaction-history-jazz-pharmaceuticals-inc-200-follow-through-indicator-30", "https://www.nasdaq.com/articles/after-hours-earnings-report-may-7-2015-cbs-cern-mnst-ca-mhk-bap-nvda-tso-jazz-mdvn-mchp", "https://www.nasdaq.com/articles/2-stocks-buy-biotech-crash-2015-04-28", "https://www.nasdaq.com/articles/big-pharma-comes-under-attack-new-hedge-fund-strategy-2015-04-26", "https://www.nasdaq.com/articles/new-hedge-fund-strategy-just-might-be-crazy-enough-work-2015-04-19", "https://www.nasdaq.com/articles/will-hedge-fund-manager-bring-down-your-biotech-stocks-2015-04-19", "https://www.nasdaq.com/articles/pfizer-inc-has-growth-problem-here-are-3-ways-change-2015-03-04", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-up-on-u.s.-approval-of-xyrem-rems-analyst-blog-2015-03-04", "https://www.nasdaq.com/articles/company-news-for-february-26-2015-corporate-summary-2015-02-26", "https://www.nasdaq.com/articles/play-hidden-ma-boom-and-beat-market-next-two-years-2015-02-26", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-tops-q4-earnings-provides-guidance-analyst-blog-2015-02-25", "https://www.nasdaq.com/articles/earnings-reaction-history-jazz-pharmaceuticals-inc-200-follow-through-indicator-29", "https://www.nasdaq.com/articles/after-hours-earnings-report-february-24-2015-hpq-eix-clr-vrsk-jazz-nly-awk-rrc-y-fslr-ndsn", "https://www.nasdaq.com/articles/commit-purchase-jazz-pharmaceuticals-110-earn-66-using-options-2015-02-10", "https://www.nasdaq.com/articles/pfizer-inc-has-growth-problem-here-are-3-ways-change-2015-03-04", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-starts-defibrotide-rolling-nda-filing-analyst-blog-2014-12-15", "https://www.nasdaq.com/articles/health-care-sector-update-12122014-jazzccxieprs-2014-12-12", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-slips-after-dosing-issue-on-jzp-386-analyst-blog-2014-12-10", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-jazz-starts-late-stage-study-on-xyrem-analyst-blog-2014-12-03", "https://www.nasdaq.com/articles/5-axes-chop-better-stocks-investment-ideas-2014-12-03", "https://www.nasdaq.com/articles/3-biotech-growth-stocks-you-can-buy-right-now-2014-11-25", "https://www.nasdaq.com/articles/riding-bull-market-these-2-momentum-etfs-2014-11-20", "https://www.nasdaq.com/articles/top-pharmaceutical-stocks-buy-2015-2014-12-20", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-starts-defibrotide-rolling-nda-filing-analyst-blog-2014-12-15", "https://www.nasdaq.com/articles/health-care-sector-update-12122014-jazzccxieprs-2014-12-12", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-slips-after-dosing-issue-on-jzp-386-analyst-blog-2014-12-10", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-jazz-starts-late-stage-study-on-xyrem-analyst-blog-2014-12-03", "https://www.nasdaq.com/articles/earnings-reaction-history-jazz-pharmaceuticals-inc-222-follow-through-indicator-30", "https://www.nasdaq.com/articles/after-hours-earnings-report-november-4-2014-foxa-pxd-fox-dvn-atvi-sbac-pba-oke-trip-jazz", "https://www.nasdaq.com/articles/bullish-two-hundred-day-moving-average-cross-jazz-2014-10-16", "https://www.nasdaq.com/articles/is-jazz-pharmaceuticals-jazz-a-great-growth-stock-tale-of-the-tape-2014-11-14", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-uses-new-cash-buy-growth-2014-10-03", "https://www.nasdaq.com/articles/top-fund-buys-chipotle-allergan-jazz-gilead-2014-10-02", "https://www.nasdaq.com/articles/shire-resolves-litigation-related-to-vyvanse-adderall-xr-analyst-blog-2014-09-25", "https://www.nasdaq.com/articles/opko-health-opk-reports-positive-data-on-rayaldee-trial-analyst-blog-2014-09-24", "https://www.nasdaq.com/articles/alcobra-finishes-follow-up-visits-on-phase-iii-trial-on-mdx-analyst-blog-2014-09-23", "https://www.nasdaq.com/articles/dynavax-dvax-completes-enrolment-for-study-on-heplisav-analyst-blog-2014-09-23", "https://www.nasdaq.com/articles/should-you-invest-corporate-tax-inversions-2014-09-16", "https://www.nasdaq.com/articles/concert-pharmaceuticals-announces-positive-ctp-354-data-analyst-blog-2014-10-15", "https://www.nasdaq.com/articles/three-stocks-top-performing-funds-facebook-baidu-gilead-2014-09-03", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-jazz-shares-march-higher-can-it-continue-tale-of-the-tape-2014-08-21", "https://www.nasdaq.com/articles/stock-market-news-for-august-14-2014-market-news-2014-08-14", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-jazz-in-focus%3A-stock-surges-8.8-tale-of-the-tape-2014-08-14", "https://www.nasdaq.com/articles/sector-update-health-care-2014-08-08-1", "https://www.nasdaq.com/articles/sector-update-health-care-shares-mixed-pre-market-tearlab-sheds-10-weak-q2-results-2014-08", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-jazz-jumps%3A-stock-moves-5.2-higher-tale-of-the-tape-2014-08-07", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-jazz-in-focus%3A-stock-rises-7.1-tale-of-the-tape-2014-09-08", "https://www.nasdaq.com/articles/first-week-march-2015-options-trading-jazz-pharmaceuticals-jazz-2014-07-22", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-concert-pharmaceuticals-start-study-analyst-blog-2014-07-22", "https://www.nasdaq.com/articles/concert-pharmaceuticals-shares-slip-despite-favorable-fda-meeting-analyst-blog-2014-07-09", "https://www.nasdaq.com/articles/biotech-stock-roundup-regado-plunges-study-update-jazz-gains-product-acquisition-deal", "https://www.nasdaq.com/articles/raptor-pharmaceuticals-ceo-to-retire-appoints-successor-analyst-blog-2014-07-08", "https://www.nasdaq.com/articles/ishares-us-pharmaceuticals-etf-experiences-big-outflow-2014-07-07", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-public-limited-company-jazz-in-focus%3A-stock-moves-6.9-higher-tale-of", "https://www.nasdaq.com/articles/earnings-up-at-jazz-pharmaceuticals-revenue-guidance-raised-analyst-blog-2014-08-06", "https://www.nasdaq.com/articles/momentum-bulls-return-jazz-2014-06-23", "https://www.nasdaq.com/articles/tuesdays-etf-movers-gdxj-xph-2014-06-10", "https://www.nasdaq.com/articles/positive-phase-iib-data-from-jazz-pharma-analyst-blog-2014-06-05", "https://www.nasdaq.com/articles/first-week-jazz-july-19th-options-trading-2014-05-20", "https://www.nasdaq.com/articles/earnings-up-at-jazz-pharma-guidance-reiterated-analyst-blog-2014-05-09", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-vbk-arcp-jazz-wab-2014-04-08", "https://www.nasdaq.com/articles/vbk-arcp-jazz-wab-large-outflows-detected-etf-2014-03-28", "https://www.nasdaq.com/articles/wall-street-positive-hopes-global-stimulus-2014-03-28", "https://www.nasdaq.com/articles/weekly-insider-sells-highlight-jazz-hd-esrx-sci-2014-03-11", "https://www.nasdaq.com/articles/sector-update-healthcare-shares-flat-higher-pre-market-biocryst-q4-results-mixed-2014-02", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-02-26-1", "https://www.nasdaq.com/articles/late-selloff-nips-healthcare-stocks-jazz-pharmaceuticals-falls-after-missing-q4", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-02-26", "https://www.nasdaq.com/articles/after-hours-earnings-report-february-25-2014-eix-avgo-rrc-sbac-wft-vrsk-nly-jazz-cbi-y-qep", "https://www.nasdaq.com/articles/first-trust-health-care-alphadex-fund-experiences-big-inflow-2014-02-24", "https://www.nasdaq.com/articles/wall-street-positive-hopes-global-stimulus-2014-03-28", "https://www.nasdaq.com/articles/bull-day-endocyte-ecyt-bull-day-2014-02-12", "https://www.nasdaq.com/articles/first-trust-health-care-alphadex-fund-experiences-big-inflow-2014-02-11", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-public-limited-company-jazz-new-analyst-report-zacks-equity-research", "https://www.nasdaq.com/articles/celgene-provides-rosy-long-term-projection-analyst-blog-2014-01-14", "https://www.nasdaq.com/articles/sucampo-scmp-worth-watching%3A-stock-rises-11.9-tale-of-the-tape-2014-01-14", "https://www.nasdaq.com/articles/cadence-pharmaceuticals-inc.-cadx-soars%3A-stock-adds-13.0-in-session-tale-of-the-tape-2014", "https://www.nasdaq.com/articles/igi-laboratories-ig-soars%3A-stock-adds-10.4-in-session-tale-of-the-tape-2014-01-14", "https://www.nasdaq.com/articles/dendreon-up-on-prelim-q4-results-analyst-blog-2014-01-14", "https://www.nasdaq.com/articles/amags-feraheme-revs-look-good-analyst-blog-2014-01-14", "https://www.nasdaq.com/articles/jazz-pharma-acquires-sleep-drug-analyst-blog-2014-01-14", "https://www.nasdaq.com/articles/avanir-gives-preliminary-q1-update-analyst-blog-2014-01-14", "https://www.nasdaq.com/articles/tesaro-tsro-jumps%3A-stock-moves-8.1-higher-tale-of-the-tape-2014-01-13", "https://www.nasdaq.com/articles/flamel-technologies-flml-in-focus%3A-stock-jumps-8.6-tale-of-the-tape-2014-01-13", "https://www.nasdaq.com/articles/repros-continues-to-gain-on-androxal-news-analyst-blog-2014-01-13", "https://www.nasdaq.com/articles/endp-agrees-to-sell-healthtronics-unit-analyst-blog-2014-01-10", "https://www.nasdaq.com/articles/receptos-rcpt-in-focus%3A-stock-moves-12.6-higher-tale-of-the-tape-2014-01-10", "https://www.nasdaq.com/articles/zogenix-zgnx-worth-watching%3A-stock-surges-16.5-tale-of-the-tape-2014-01-09", "https://www.nasdaq.com/articles/abraxane-label-expansion-lifts-celgene-analyst-blog-2014-01-08", "https://www.nasdaq.com/articles/bullish-on-actelion-analyst-blog-2014-01-03", "https://www.nasdaq.com/articles/redhill-biopharma-sells-ads-again-analyst-blog-2014-01-03", "https://www.nasdaq.com/articles/flamel-technologies-sa-flml-jumps%3A-stock-adds-8.7-tale-of-the-tape-2014-01-06", "https://www.nasdaq.com/articles/ariad-to-present-at-jpm-conference-analyst-blog-2014-01-06", "https://www.nasdaq.com/articles/intercept-to-provide-update-on-pipeline-analyst-blog-2014-01-06", "https://www.nasdaq.com/articles/biocryst-attains-52-week-high-analyst-blog-2014-01-06", "https://www.nasdaq.com/articles/gentium-upgraded-to-strong-buy-analyst-blog-2014-01-03", "https://www.nasdaq.com/articles/acura-confirms-%2410m-loan-agreement-analyst-blog-2014-01-03", "https://www.nasdaq.com/articles/bullish-on-actelion-analyst-blog-2014-01-03", "https://www.nasdaq.com/articles/redhill-biopharma-sells-ads-again-analyst-blog-2014-01-03", "https://www.nasdaq.com/articles/flamel-technologies-sa-flml-jumps%3A-stock-adds-8.7-tale-of-the-tape-2014-01-06", "https://www.nasdaq.com/articles/perrigo-maintained-at-neutral-analyst-blog-2014-01-03", "https://www.nasdaq.com/articles/pluristem-touches-52-week-high-analyst-blog-2014-01-03", "https://www.nasdaq.com/articles/bullish-on-gilead-analyst-blog-2014-01-02", "https://www.nasdaq.com/articles/valeant-attains-52-week-high-analyst-blog-2014-01-02", "https://www.nasdaq.com/articles/chemocentryx-ccxi-jumps%3A-stock-up-5.7-tale-of-the-tape-2014-01-02", "https://www.nasdaq.com/articles/new-patent-for-sn-38-conjugates-at-immu-analyst-blog-2014-01-02", "https://www.nasdaq.com/articles/pipeline-progress-at-heat-biologics-analyst-blog-2014-01-02", "https://www.nasdaq.com/articles/salix-pharma-acquires-santarus-analyst-blog-2014-01-03", "https://www.nasdaq.com/articles/update-on-astrazenecas-crestor-analyst-blog-2013-12-30", "https://www.nasdaq.com/articles/update-on-shire-viropharma-deal-analyst-blog-2013-12-30", "https://www.nasdaq.com/articles/update-on-amarins-vascepa-analyst-blog-2013-12-27", "https://www.nasdaq.com/articles/ventrus-biosciences-vtus-jumps%3A-stock-up-6.8-tale-of-the-tape-2013-12-27", "https://www.nasdaq.com/articles/inovio-pharmaceuticals-ino-soars%3A-stock-zooms-20.2-tale-of-the-tape-2013-12-27", "https://www.nasdaq.com/articles/durata-progresses-with-dalbavancin-analyst-blog-2013-12-27", "https://www.nasdaq.com/articles/united-therapeutics-surges-after-fda-approval-analyst-blog-2013-12-27", "https://www.nasdaq.com/articles/update-on-redhill-biopharmas-pipeline-analyst-blog-2013-12-30", "https://www.nasdaq.com/articles/update-on-astrazenecas-crestor-analyst-blog-2013-12-30", "https://www.nasdaq.com/articles/update-on-shire-viropharma-deal-analyst-blog-2013-12-30", "https://www.nasdaq.com/articles/update-on-amarins-vascepa-analyst-blog-2013-12-27", "https://www.nasdaq.com/articles/pipeline-update-on-santarus-candidate-analyst-blog-2013-12-26", "https://www.nasdaq.com/articles/sucampo-reports-data-analyst-blog-2013-12-26", "https://www.nasdaq.com/articles/update-on-ariads-iclusig-analyst-blog-2013-12-26", "https://www.nasdaq.com/articles/eu-approves-actelions-opsumit-analyst-blog-2013-12-24", "https://www.nasdaq.com/articles/update-on-biospecifics-auxiliums-xiaflex-analyst-blog-2013-12-27", "https://www.nasdaq.com/articles/pipeline-update-on-aratana-analyst-blog-2013-12-27", "https://www.nasdaq.com/articles/update-on-mdcos-pipeline-analyst-blog-2013-12-27", "https://www.nasdaq.com/articles/synergy-pharma-progresses-with-plecanatide-analyst-blog-2013-12-26", "https://www.nasdaq.com/articles/pipeline-update-on-santarus-candidate-analyst-blog-2013-12-26", "https://www.nasdaq.com/articles/sucampo-reports-data-analyst-blog-2013-12-26", "https://www.nasdaq.com/articles/update-on-ariads-iclusig-analyst-blog-2013-12-26", "https://www.nasdaq.com/articles/eu-approves-actelions-opsumit-analyst-blog-2013-12-24", "https://www.nasdaq.com/articles/tesaro-plunges-on-study-results-analyst-blog-2013-12-24", "https://www.nasdaq.com/articles/ariad-pharmaceuticals-aria-catches-eye%3A-stock-jumps-8.9-tale-of-the-tape-2013-12-24", "https://www.nasdaq.com/articles/athersys-inc.-athx-jumps%3A-stock-up-6.9-tale-of-the-tape-2013-12-24", "https://www.nasdaq.com/articles/can-fite-biopharma-canf-soars%3A-stock-zooms-17.5-tale-of-the-tape-2013-12-24", "https://www.nasdaq.com/articles/pipeline-progress-at-athersys-analyst-blog-2013-12-24", "https://www.nasdaq.com/articles/update-on-astrazenecas-nexium-competition-analyst-blog-2013-12-24", "https://www.nasdaq.com/articles/biocrysts-peramivir-filed-in-the-u.s.-analyst-blog-2013-12-24", "https://www.nasdaq.com/articles/update-on-glaxos-hiv-drugs-analyst-blog-2013-12-24", "https://www.nasdaq.com/articles/tesaro-plunges-on-study-results-analyst-blog-2013-12-24", "https://www.nasdaq.com/articles/apricus-biosciences-apri-soars%3A-stock-up-10.6-tale-of-the-tape-2013-12-23", "https://www.nasdaq.com/articles/jazz-pharma-to-acquire-gentium-analyst-blog-2013-12-20", "https://www.nasdaq.com/articles/alimera-sciences-alim-soars%3A-stock-zooms-62.8-tale-of-the-tape-2013-12-20", "https://www.nasdaq.com/articles/psivida-corp.-psdv-jumps%3A-stock-up-32.0-tale-of-the-tape-2013-12-20", "https://www.nasdaq.com/articles/update-on-biolinerxs-bl-7010-analyst-blog-2013-12-20", "https://www.nasdaq.com/articles/mid-afternoon-market-update-textron-rises-markets-rise-across-board-2013-12-20", "https://www.nasdaq.com/articles/novartis-sandoz-receives-airflusal-forspiro-approval-analyst-blog-2013-12-19", "https://www.nasdaq.com/articles/bmy-to-sell-diabetes-portfolio-analyst-blog-2013-12-20", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-rally-blackberry-posts-q3-loss-2013-12-20", "https://www.nasdaq.com/articles/ariad-pharmaceuticals-aria-worth-watching%3A-stock-surges-19.7-tale-of-the-tape-2013-12-19", "https://www.nasdaq.com/articles/halozyme-therapeutics-halo-jumps%3A-stock-up-16.6-tale-of-the-tape-2013-12-19", "https://www.nasdaq.com/articles/positive-data-on-gileads-sovaldi-analyst-blog-2013-12-19", "https://www.nasdaq.com/articles/update-on-psividas-iluvien-analyst-blog-2013-12-19", "https://www.nasdaq.com/articles/redhill-doses-first-patient-for-eradicate-study-analyst-blog-2013-12-18", "https://www.nasdaq.com/articles/sucampos-amitiza-progresses-analyst-blog-2013-12-18", "https://www.nasdaq.com/articles/glaxo-thrx-drug-gets-fda-nod-analyst-blog-2013-12-19", "https://www.nasdaq.com/articles/hyperion-therapeutics-hptx-jumps%3A-stock-adds-5.2-tale-of-the-tape-2013-12-19", "https://www.nasdaq.com/articles/ariad-pharmaceuticals-aria-worth-watching%3A-stock-surges-19.7-tale-of-the-tape-2013-12-19", "https://www.nasdaq.com/articles/halozyme-therapeutics-halo-jumps%3A-stock-up-16.6-tale-of-the-tape-2013-12-19", "https://www.nasdaq.com/articles/positive-data-on-gileads-sovaldi-analyst-blog-2013-12-19", "https://www.nasdaq.com/articles/update-on-psividas-iluvien-analyst-blog-2013-12-19", "https://www.nasdaq.com/articles/redhill-doses-first-patient-for-eradicate-study-analyst-blog-2013-12-18", "https://www.nasdaq.com/articles/sucampos-amitiza-progresses-analyst-blog-2013-12-18", "https://www.nasdaq.com/articles/pipeline-progress-at-cempra-analyst-blog-2013-12-18", "https://www.nasdaq.com/articles/gileads-sovaldi-holds-promise-analyst-blog-2013-12-18", "https://www.nasdaq.com/articles/nupathe-inc.-path-in-focus%3A-stock-zooms-47.4-tale-of-the-tape-2013-12-17", "https://www.nasdaq.com/articles/acelrx-pharmaceuticals-acrx-jumps%3A-stock-up-17.9-tale-of-the-tape-2013-12-17", "https://www.nasdaq.com/articles/endo-to-acquire-nupathe-analyst-blog-2013-12-17", "https://www.nasdaq.com/articles/update-on-alexions-voluntary-recall-analyst-blog-2013-12-16", "https://www.nasdaq.com/articles/update-on-endos-ams-unit-analyst-blog-2013-12-16", "https://www.nasdaq.com/articles/peregrine-reports-in-line-loss-analyst-blog-2013-12-11", "https://www.nasdaq.com/articles/data-on-astrazenecas-lesinurad-analyst-blog-2013-12-16", "https://www.nasdaq.com/articles/immunogen-amends-lilly-agreement-analyst-blog-2013-12-16", "https://www.nasdaq.com/articles/data-presented-by-celgene-analyst-blog-2013-12-09", "https://www.nasdaq.com/articles/biospecifics-technologies-corp.-bstc-in-focus%3A-stock-moves-6.5-higher-tale-of-the-tape", "https://www.nasdaq.com/articles/puma-biotechnology-pbyi-jumps%3A-stock-up-11.7-tale-of-the-tape-2013-12-09", "https://www.nasdaq.com/articles/ariad-loses-as-ema-deliberates-on-iclusig-analyst-blog-2013-12-09", "https://www.nasdaq.com/articles/positive-data-on-shires-lifitegrast-analyst-blog-2013-12-06", "https://www.nasdaq.com/articles/anacor-pharmaceuticals-anac-jumps%3A-stock-rises-5.7-tale-of-the-tape-2013-12-06", "https://www.nasdaq.com/articles/coronado-biosciences-cndo-jumps%3A-stock-adds-13.4-in-session-tale-of-the-tape-2013-12-10", "https://www.nasdaq.com/articles/celgene-rises-on-positive-revlimid-data-analyst-blog-2013-12-10", "https://www.nasdaq.com/articles/data-presented-by-celgene-analyst-blog-2013-12-09", "https://www.nasdaq.com/articles/biospecifics-technologies-corp.-bstc-in-focus%3A-stock-moves-6.5-higher-tale-of-the-tape", "https://www.nasdaq.com/articles/puma-biotechnology-pbyi-jumps%3A-stock-up-11.7-tale-of-the-tape-2013-12-09", "https://www.nasdaq.com/articles/ariad-loses-as-ema-deliberates-on-iclusig-analyst-blog-2013-12-09", "https://www.nasdaq.com/articles/positive-data-on-shires-lifitegrast-analyst-blog-2013-12-06", "https://www.nasdaq.com/articles/anacor-pharmaceuticals-anac-jumps%3A-stock-rises-5.7-tale-of-the-tape-2013-12-06", "https://www.nasdaq.com/articles/coronado-biosciences-cndo-jumps%3A-stock-adds-13.4-in-session-tale-of-the-tape-2013-12-10", "https://www.nasdaq.com/articles/update-on-kalobios-kb004-analyst-blog-2013-12-06", "https://www.nasdaq.com/articles/update-on-paciras-exparel-analyst-blog-2013-12-06", "https://www.nasdaq.com/articles/astrazeneca-wins-prilosec-damages-analyst-blog-2013-12-05", "https://www.nasdaq.com/articles/nda-for-acelrxs-zalviso-accepted-analyst-blog-2013-12-05", "https://www.nasdaq.com/articles/impax-settles-litigation-with-purdue-pharma-analyst-blog-2013-12-05", "https://www.nasdaq.com/articles/jazz-briefs-at-healthcare-conference-analyst-blog-2013-12-05", "https://www.nasdaq.com/articles/final-guidance-from-nice-for-psividas-iluvien-analyst-blog-2013-12-05", "https://www.nasdaq.com/articles/receptos-rcpt-in-focus%3A-stock-moves-21.8-higher-tale-of-the-tape-2013-12-06", "https://www.nasdaq.com/articles/galectin-therapeutics-galt-in-focus%3A-stock-moves-up-13.2-tale-of-the-tape-2013-12-04", "https://www.nasdaq.com/articles/data-on-nvos-diabetes-drugs-analyst-blog-2013-12-04", "https://www.nasdaq.com/articles/forest-labs-up-on-strategic-initiatives-analyst-blog-2013-12-03", "https://www.nasdaq.com/articles/strength-seen-in-lannett-company-lci%3A-stock-gains-8.7-tale-of-the-tape-2013-12-03", "https://www.nasdaq.com/articles/can-the-rally-in-jazz-pharmaceuticals-plc-jazz-shares-continue-tale-of-the-tape-2013-12-03", "https://www.nasdaq.com/articles/actelions-update-on-opsumit-analyst-blog-2013-12-03", "https://www.nasdaq.com/articles/allergan-sells-off-obesity-business-analyst-blog-2013-12-03", "https://www.nasdaq.com/articles/cadence-pharmaceuticals-inc.-cadx-jumps%3A-stock-rises-6.2-tale-of-the-tape-2013-12-04", "https://www.nasdaq.com/articles/athersys-to-raise-funds-analyst-blog-2013-12-02", "https://www.nasdaq.com/articles/impax-labs-attains-52-week-high-analyst-blog-2013-12-02", "https://www.nasdaq.com/articles/back-to-neutral-on-endo-health-analyst-blog-2013-11-29", "https://www.nasdaq.com/articles/amag-raised-to-strong-buy-analyst-blog-2013-11-29", "https://www.nasdaq.com/articles/bioscrip-bios-jumps%3A-stock-moves-17.3-higher-tale-of-the-tape-2013-11-29", "https://www.nasdaq.com/articles/pipeline-progress-at-ventrus-analyst-blog-2013-11-29", "https://www.nasdaq.com/articles/zogenix-zgnx-worth-a-look%3A-stock-adds-7.3-in-session-tale-of-the-tape-2013-11-27", "https://www.nasdaq.com/articles/aeterna-zentaris-closes-public-offering-analyst-blog-2013-12-02", "https://www.nasdaq.com/articles/enanta-pharmaceuticals-enta-looks-good%3A-stock-adds-6.2-tale-of-the-tape-2013-11-26", "https://www.nasdaq.com/articles/good-news-for-apricus-from-italy-analyst-blog-2013-11-26", "https://www.nasdaq.com/articles/alnylam-earns-milestone-payment-analyst-blog-2013-11-26", "https://www.nasdaq.com/articles/strength-seen-in-ariad-pharmaceuticals-aria%3A-stock-zooms-35.5-tale-of-the-tape-2013-11-25", "https://www.nasdaq.com/articles/continuation-of-ariads-iclusig-in-eu-analyst-blog-2013-11-25", "https://www.nasdaq.com/articles/data-on-auxilium-pharmas-xiaflex-analyst-blog-2013-11-22", "https://www.nasdaq.com/articles/regulatory-setback-for-forest-gedeon-analyst-blog-2013-11-22", "https://www.nasdaq.com/articles/ligand-pharmaceuticals-lgnd-jumps%3A-stock-rises-5.5-tale-of-the-tape-2013-11-27", "https://www.nasdaq.com/articles/update-from-qlti-shares-up-analyst-blog-2013-11-21", "https://www.nasdaq.com/articles/amag-upgraded-to-strong-buy-analyst-blog-2013-11-21", "https://www.nasdaq.com/articles/athersys-narrows-loss-shares-rise-analyst-blog-2013-11-21", "https://www.nasdaq.com/articles/qlt-qlti-surges%3A-stock-moves-11.8-higher-tale-of-the-tape-2013-11-21", "https://www.nasdaq.com/articles/orphan-drug-status-for-gentiums-defitelio-analyst-blog-2013-11-21", "https://www.nasdaq.com/articles/jazz-pharma-attains-52-week-high-analyst-blog-2013-11-20", "https://www.nasdaq.com/articles/dynavax-technologies-dvax-in-focus%3A-stock-moves-5.8-higher-tale-of-the-tape-2013-11-20", "https://www.nasdaq.com/articles/strength-seen-in-intellipharmaceutics-ipci%3A-stock-shoots-161.9-tale-of-the-tape-2013-11-20", "https://www.nasdaq.com/articles/biospecifics-technologies-bstc-looks-good%3A-stock-moves-9.5-higher-tale-of-the-tape-2013-11", "https://www.nasdaq.com/articles/market-reacts-to-vandas-hetlioz-analyst-blog-2013-11-19", "https://www.nasdaq.com/articles/loss-widens-at-apricus-analyst-blog-2013-11-18", "https://www.nasdaq.com/articles/narrower-loss-at-orexigen-in-q3-analyst-blog-2013-11-14", "https://www.nasdaq.com/articles/fda-accepts-nps-pharmas-snda-analyst-blog-2013-11-14", "https://www.nasdaq.com/articles/anacor-rises-on-positive-data-analyst-blog-2013-11-14", "https://www.nasdaq.com/articles/can-the-uptrend-continue-for-jazz-pharmaceuticals-plc-ordinary-shares-jazz-tale-of-the", "https://www.nasdaq.com/articles/synergy-pharmas-q3-loss-narrower-than-expected-analyst-blog-2013-11-15", "https://www.nasdaq.com/articles/igi-laboratories-ig-in-focus%3A-stock-surges-14.5-tale-of-the-tape-2013-11-15", "https://www.nasdaq.com/articles/narrow-than-expected-loss-at-pernix-analyst-blog-2013-11-14", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-jazz-worth-watching%3A-stock-rises-8.7-tale-of-the-tape-2013-11-14", "https://www.nasdaq.com/articles/narrower-loss-at-orexigen-in-q3-analyst-blog-2013-11-14", "https://www.nasdaq.com/articles/fda-accepts-nps-pharmas-snda-analyst-blog-2013-11-14", "https://www.nasdaq.com/articles/anacor-rises-on-positive-data-analyst-blog-2013-11-14", "https://www.nasdaq.com/articles/mallinckrodt-misses-on-earnings-sales-analyst-blog-2013-11-12", "https://www.nasdaq.com/articles/actelions-opsumit-cleared-in-canada-analyst-blog-2013-11-13", "https://www.nasdaq.com/articles/vanda-shoots-up-ahead-of-fda-panel-analyst-blog-2013-11-13", "https://www.nasdaq.com/articles/narrower-q3-loss-at-supernus-analyst-blog-2013-11-13", "https://www.nasdaq.com/articles/astrazeneca-to-invest-in-new-zoladex-facility-analyst-blog-2013-11-12", "https://www.nasdaq.com/articles/trade-earnings-jazz-pharmaceuticals-inc-2013-11-05", "https://www.nasdaq.com/articles/stock-picking-secrets-whales-weekend-wisdom-2013-10-25", "https://www.nasdaq.com/articles/gsk-genmab-seek-arzerra-eu-approval-analyst-blog-2013-10-07", "https://www.nasdaq.com/articles/narrower-than-expected-loss-at-arqule-analyst-blog-2013-11-11", "https://www.nasdaq.com/articles/valeants-jublia-approved-in-canada-analyst-blog-2013-10-07", "https://www.nasdaq.com/articles/good-news-for-valeant-analyst-blog-2013-10-04", "https://www.nasdaq.com/articles/update-on-nps-pharmas-portfolio-analyst-blog-2013-10-04", "https://www.nasdaq.com/articles/data-on-arqules-tivantinib-analyst-blog-2013-10-04", "https://www.nasdaq.com/articles/data-on-gw-pharmas-sativex-analyst-blog-2013-10-03", "https://www.nasdaq.com/articles/update-on-paciras-exparel-analyst-blog-2013-10-03", "https://www.nasdaq.com/articles/update-on-anacors-tavaborole-analyst-blog-2013-10-03", "https://www.nasdaq.com/articles/incyte-progresses-with-jak-inhibitors-analyst-blog-2013-10-07", "https://www.nasdaq.com/articles/valeants-jublia-approved-in-canada-analyst-blog-2013-10-07", "https://www.nasdaq.com/articles/good-news-for-valeant-analyst-blog-2013-10-04", "https://www.nasdaq.com/articles/update-on-nps-pharmas-portfolio-analyst-blog-2013-10-04", "https://www.nasdaq.com/articles/data-on-arqules-tivantinib-analyst-blog-2013-10-04", "https://www.nasdaq.com/articles/data-on-gw-pharmas-sativex-analyst-blog-2013-10-03", "https://www.nasdaq.com/articles/update-on-paciras-exparel-analyst-blog-2013-10-03", "https://www.nasdaq.com/articles/update-on-anacors-tavaborole-analyst-blog-2013-10-03", "https://www.nasdaq.com/articles/pipeline-progress-at-alnylam-analyst-blog-2013-10-03", "https://www.nasdaq.com/articles/label-expansion-for-roches-perjeta-analyst-blog-2013-10-02", "https://www.nasdaq.com/articles/glaxo-to-divest-arixtra-and-fraxiparine-analyst-blog-2013-10-01", "https://www.nasdaq.com/articles/cempra-cemp-worth-a-look%3A-stock-up-6.1-analyst-blog-2013-10-01", "https://www.nasdaq.com/articles/data-on-cytoris-cell-therapy-analyst-blog-2013-09-23", "https://www.nasdaq.com/articles/data-on-kalobios-kb001-published-analyst-blog-2013-09-20", "https://www.nasdaq.com/articles/protalix-raises-funds-analyst-blog-2013-09-19", "https://www.nasdaq.com/articles/coronado-biosciences-tso-in-phase-ii-study-analyst-blog-2013-09-19", "https://www.nasdaq.com/articles/update-on-amarin-study-analyst-blog-2013-09-26", "https://www.nasdaq.com/articles/vivus-hopes-tied-to-qsymia-analyst-blog-2013-09-25", "https://www.nasdaq.com/articles/synageva-prices-public-offering-analyst-blog-2013-09-25", "https://www.nasdaq.com/articles/strength-seen-in-ptc-therapeutics-ptct%3A-stock-surges-25.7-analyst-blog-2013-09-24", "https://www.nasdaq.com/articles/data-on-cytoris-cell-therapy-analyst-blog-2013-09-23", "https://www.nasdaq.com/articles/data-on-kalobios-kb001-published-analyst-blog-2013-09-20", "https://www.nasdaq.com/articles/protalix-raises-funds-analyst-blog-2013-09-19", "https://www.nasdaq.com/articles/positive-news-on-roches-perjeta-analyst-blog-2013-09-13", "https://www.nasdaq.com/articles/encouraging-data-on-kytheras-atx-101-analyst-blog-2013-09-17", "https://www.nasdaq.com/articles/roche-and-inovio-tie-up-analyst-blog-2013-09-11", "https://www.nasdaq.com/articles/encouraging-data-on-xenoports-xp23829-analyst-blog-2013-09-11", "https://www.nasdaq.com/articles/catalyst-pharma-raises-funds-analyst-blog-2013-09-11", "https://www.nasdaq.com/articles/novartis-ties-up-with-regenerex-analyst-blog-2013-09-10", "https://www.nasdaq.com/articles/standard-review-for-mrk-fertility-drug-analyst-blog-2013-09-10", "https://www.nasdaq.com/articles/encouraging-data-on-oncolytics-reolysin-analyst-blog-2013-09-10", "https://www.nasdaq.com/articles/update-on-xenoports-horizant-analyst-blog-2013-09-12", "https://www.nasdaq.com/articles/data-on-novartis-ultibro-breezhaler-analyst-blog-2013-09-12", "https://www.nasdaq.com/articles/roche-and-inovio-tie-up-analyst-blog-2013-09-11", "https://www.nasdaq.com/articles/encouraging-data-on-xenoports-xp23829-analyst-blog-2013-09-11", "https://www.nasdaq.com/articles/catalyst-pharma-raises-funds-analyst-blog-2013-09-11", "https://www.nasdaq.com/articles/novartis-ties-up-with-regenerex-analyst-blog-2013-09-10", "https://www.nasdaq.com/articles/standard-review-for-mrk-fertility-drug-analyst-blog-2013-09-10", "https://www.nasdaq.com/articles/encouraging-data-on-oncolytics-reolysin-analyst-blog-2013-09-10", "https://www.nasdaq.com/articles/update-on-xenoports-horizant-analyst-blog-2013-09-12", "https://www.nasdaq.com/articles/vivus-gets-a-new-ceo-analyst-blog-2013-09-09", "https://www.nasdaq.com/articles/setback-for-glaxos-cancer-pipeline-analyst-blog-2013-09-06", "https://www.nasdaq.com/articles/otsuka-pharma-to-acquire-astex-pharma-shares-up-analyst-blog-2013-09-06", "https://www.nasdaq.com/articles/data-on-cempras-solithromycin-analyst-blog-2013-09-06", "https://www.nasdaq.com/articles/encouraging-data-on-roches-lampalizumab-analyst-blog-2013-08-30", "https://www.nasdaq.com/articles/swissmedic-negative-on-apricus-vitaros-analyst-blog-2013-08-30", "https://www.nasdaq.com/articles/european-approval-for-glaxos-tafinlar-analyst-blog-2013-09-04", "https://www.nasdaq.com/articles/sanofi-unveils-bond-issue-pricing-analyst-blog-2013-09-04", "https://www.nasdaq.com/articles/setback-for-arqule-analyst-blog-2013-09-04", "https://www.nasdaq.com/articles/data-on-novartis-rlx030-analyst-blog-2013-09-03", "https://www.nasdaq.com/articles/eu-nod-for-roches-new-formulation-of-herceptin-analyst-blog-2013-09-03", "https://www.nasdaq.com/articles/aradigm-grifols-collaborate-analyst-blog-2013-09-03", "https://www.nasdaq.com/articles/encouraging-data-on-roches-lampalizumab-analyst-blog-2013-08-30", "https://www.nasdaq.com/articles/astellas-astagraf-xl-launched-in-u.s.-analyst-blog-2013-08-23", "https://www.nasdaq.com/articles/opko-acquires-prolor-biotech-analyst-blog-2013-08-30", "https://www.nasdaq.com/articles/breakthrough-therapy-for-novartis-analyst-blog-2013-08-21", "https://www.nasdaq.com/articles/abbott-acquires-optimedica-analyst-blog-2013-08-21", "https://www.nasdaq.com/articles/hyperions-loss-narrows-y-y-analyst-blog-2013-08-20", "https://www.nasdaq.com/articles/impax-surpasses-earnings-estimates-analyst-blog-2013-08-13", "https://www.nasdaq.com/articles/loss-widens-at-omeros-in-q2-analyst-blog-2013-08-12", "https://www.nasdaq.com/articles/corcepts-q2-loss-in-line-with-expectations-analyst-blog-2013-08-12", "https://www.nasdaq.com/articles/setback-for-novartis-afinitor-analyst-blog-2013-08-09", "https://www.nasdaq.com/articles/positive-results-from-fibrocell-science-analyst-blog-2013-08-22", "https://www.nasdaq.com/articles/breakthrough-therapy-for-novartis-analyst-blog-2013-08-21", "https://www.nasdaq.com/articles/abbott-acquires-optimedica-analyst-blog-2013-08-21", "https://www.nasdaq.com/articles/hyperions-loss-narrows-y-y-analyst-blog-2013-08-20", "https://www.nasdaq.com/articles/valeant-acquires-bausch-lomb-analyst-blog-2013-08-07", "https://www.nasdaq.com/articles/oncogenex-ogx-427-in-spruce-study-analyst-blog-2013-08-07", "https://www.nasdaq.com/articles/loss-widens-at-vivus-analyst-blog-2013-08-07", "https://www.nasdaq.com/articles/trade-earnings-jazz-pharmaceuticals-inc-2013-08-06", "https://www.nasdaq.com/articles/valeant-tops-on-earnings-ups-guidance-analyst-blog-2013-08-08", "https://www.nasdaq.com/articles/jazz-pharma-posts-higher-earnings-revs-analyst-blog-2013-08-08", "https://www.nasdaq.com/articles/santarus-tops-on-earnings-revs-analyst-blog-2013-08-08", "https://www.nasdaq.com/articles/in-line-loss-at-orexigen-in-q2-analyst-blog-2013-08-07", "https://www.nasdaq.com/articles/valeant-acquires-bausch-lomb-analyst-blog-2013-08-07", "https://www.nasdaq.com/articles/oncogenex-ogx-427-in-spruce-study-analyst-blog-2013-08-07", "https://www.nasdaq.com/articles/loss-widens-at-vivus-analyst-blog-2013-08-07", "https://www.nasdaq.com/articles/trade-earnings-jazz-pharmaceuticals-inc-2013-08-06", "https://www.nasdaq.com/articles/valeant-tops-on-earnings-ups-guidance-analyst-blog-2013-08-08", "https://www.nasdaq.com/articles/arena-pharmas-q2-earnings-soar-analyst-blog-2013-08-05", "https://www.nasdaq.com/articles/label-expansion-for-novartis-menveo-analyst-blog-2013-08-05", "https://www.nasdaq.com/articles/vphm-misses-on-earnings-revs-analyst-blog-2013-08-02", "https://www.nasdaq.com/articles/aeterna-initiates-phase-iii-study-on-aezs-108-analyst-blog-2013-08-02", "https://www.nasdaq.com/articles/wider-loss-at-cadx-in-q2-analyst-blog-2013-08-01", "https://www.nasdaq.com/articles/pipeline-progress-at-nektar-analyst-blog-2013-07-31", "https://www.nasdaq.com/articles/q2-loss-at-aegerion-wider-than-expected-analyst-blog-2013-07-31", "https://www.nasdaq.com/articles/shires-earnings-grow-in-q2-analyst-blog-2013-07-29", "https://www.nasdaq.com/articles/arena-pharma-cy-biotech-unite-for-belviq-analyst-blog-2013-07-29", "https://www.nasdaq.com/articles/good-news-for-bayer-analyst-blog-2013-07-29", "https://www.nasdaq.com/articles/corcept-makes-ties-with-idis-analyst-blog-2013-07-25", "https://www.nasdaq.com/articles/questcor-to-start-phase-ii-study-analyst-blog-2013-07-25", "https://www.nasdaq.com/articles/earnings-up-at-the-medicines-co.-analyst-blog-2013-07-25", "https://www.nasdaq.com/articles/earnings-beat-at-alexion-view-upped-analyst-blog-2013-07-25", "https://www.nasdaq.com/articles/narrower-than-expected-loss-at-biomarin-analyst-blog-2013-07-26", "https://www.nasdaq.com/articles/shires-earnings-revs-increase-in-q2-analyst-blog-2013-07-26", "https://www.nasdaq.com/articles/glaxo-revs-up-earnings-down-analyst-blog-2013-07-25", "https://www.nasdaq.com/articles/mercks-vorapaxar-nda-accepted-analyst-blog-2013-07-25", "https://www.nasdaq.com/articles/corcept-makes-ties-with-idis-analyst-blog-2013-07-25", "https://www.nasdaq.com/articles/questcor-to-start-phase-ii-study-analyst-blog-2013-07-25", "https://www.nasdaq.com/articles/earnings-up-at-the-medicines-co.-analyst-blog-2013-07-25", "https://www.nasdaq.com/articles/tthi-eli-lilly-ink-deal-analyst-blog-2013-07-24", "https://www.nasdaq.com/articles/bristol-myers-reports-in-line-earnings-analyst-blog-2013-07-25", "https://www.nasdaq.com/articles/forest-labs-beats-on-earnings-revs-analyst-blog-2013-07-23", "https://www.nasdaq.com/articles/santarus-progresses-uceris-study-analyst-blog-2013-07-23", "https://www.nasdaq.com/articles/ligand-azure-collaborate-analyst-blog-2013-07-23", "https://www.nasdaq.com/articles/intellipharmaceutics-up-on-positive-data-analyst-blog-2013-07-22", "https://www.nasdaq.com/articles/insmed-prices-public-offering-analyst-blog-2013-07-22", "https://www.nasdaq.com/articles/u.s.-launch-of-astellas-astagraf-xl-analyst-blog-2013-07-22", "https://www.nasdaq.com/articles/pacira-reports-new-data-analyst-blog-2013-07-19", "https://www.nasdaq.com/articles/cadence-pharma-soars-ahead-of-2q-analyst-blog-2013-07-23", "https://www.nasdaq.com/articles/forest-labs-beats-on-earnings-revs-analyst-blog-2013-07-23", "https://www.nasdaq.com/articles/santarus-progresses-uceris-study-analyst-blog-2013-07-23", "https://www.nasdaq.com/articles/ligand-azure-collaborate-analyst-blog-2013-07-23", "https://www.nasdaq.com/articles/intellipharmaceutics-up-on-positive-data-analyst-blog-2013-07-22", "https://www.nasdaq.com/articles/insmed-prices-public-offering-analyst-blog-2013-07-22", "https://www.nasdaq.com/articles/u.s.-launch-of-astellas-astagraf-xl-analyst-blog-2013-07-22", "https://www.nasdaq.com/articles/pacira-reports-new-data-analyst-blog-2013-07-19", "https://www.nasdaq.com/articles/cadence-pharma-soars-ahead-of-2q-analyst-blog-2013-07-23", "https://www.nasdaq.com/articles/chelseas-nda-for-northera-accepted-analyst-blog-2013-07-19", "https://www.nasdaq.com/articles/positive-data-from-emergents-biothrax-analyst-blog-2013-07-11", "https://www.nasdaq.com/articles/biodelivery-announces-%2420m-debt-financing-analyst-blog-2013-07-10", "https://www.nasdaq.com/articles/warner-chilcott-still-in-neutral-lane-analyst-blog-2013-07-09", "https://www.nasdaq.com/articles/santarus-achieves-new-52-week-high-analyst-blog-2013-07-09", "https://www.nasdaq.com/articles/lilly-boehringer-candidate-under-eu-review-analyst-blog-2013-07-09", "https://www.nasdaq.com/articles/array-loxo-collaborate-analyst-blog-2013-07-11", "https://www.nasdaq.com/articles/prestige-brands-acquires-care-pharma-analyst-blog-2013-07-11", "https://www.nasdaq.com/articles/gw-pharmas-sativex-launched-in-italy-analyst-blog-2013-07-11", "https://www.nasdaq.com/articles/positive-data-from-emergents-biothrax-analyst-blog-2013-07-11", "https://www.nasdaq.com/articles/biodelivery-announces-%2420m-debt-financing-analyst-blog-2013-07-10", "https://www.nasdaq.com/articles/biomarin-stays-neutral-analyst-blog-2013-07-08", "https://www.nasdaq.com/articles/jazz-pharma-touches-52-week-high-analyst-blog-2013-07-08", "https://www.nasdaq.com/articles/ariads-iclusig-approved-in-eu-analyst-blog-2013-07-05", "https://www.nasdaq.com/articles/bayer-initiates-phase-iii-study-analyst-blog-2013-07-09", "https://www.nasdaq.com/articles/takeda-withdraws-maa-for-omontys-analyst-blog-2013-07-05", "https://www.nasdaq.com/articles/psivida-starts-phase-iii-study-analyst-blog-2013-07-05", "https://www.nasdaq.com/articles/zoetis-looking-to-expand-analyst-blog-2013-07-03", "https://www.nasdaq.com/articles/avanir-optinose-collaborate-analyst-blog-2013-07-03", "https://www.nasdaq.com/articles/positive-data-from-forest-labs-analyst-blog-2013-07-02", "https://www.nasdaq.com/articles/mannkind-reaches-financing-deal-analyst-blog-2013-07-02", "https://www.nasdaq.com/articles/yet-another-setback-for-bayer-jnjs-xarelto-analyst-blog-2013-07-02", "https://www.nasdaq.com/articles/good-news-for-omeros-on-oms302-analyst-blog-2013-07-05", "https://www.nasdaq.com/articles/takeda-withdraws-maa-for-omontys-analyst-blog-2013-07-05", "https://www.nasdaq.com/articles/psivida-starts-phase-iii-study-analyst-blog-2013-07-05", "https://www.nasdaq.com/articles/zoetis-looking-to-expand-analyst-blog-2013-07-03", "https://www.nasdaq.com/articles/avanir-optinose-collaborate-analyst-blog-2013-07-03", "https://www.nasdaq.com/articles/positive-data-from-forest-labs-analyst-blog-2013-07-02", "https://www.nasdaq.com/articles/celgene-inks-oncology-deal-analyst-blog-2013-06-27", "https://www.nasdaq.com/articles/astellas-vical-start-transvax-phase-iii-study-analyst-blog-2013-06-27", "https://www.nasdaq.com/articles/avanir-completes-prime-enrollment-analyst-blog-2013-07-02", "https://www.nasdaq.com/articles/pluristem-cha-collaborate-in-south-korea-analyst-blog-2013-06-27", "https://www.nasdaq.com/articles/us-exclusivity-for-raptors-procysbi-analyst-blog-2013-06-26", "https://www.nasdaq.com/articles/cytokinetics-astellas-collaborate-analyst-blog-2013-06-26", "https://www.nasdaq.com/articles/eu-approval-for-avanirs-nuedexta-analyst-blog-2013-06-26", "https://www.nasdaq.com/articles/new-study-on-xoma-serviers-gevokizumab-analyst-blog-2013-06-26", "https://www.nasdaq.com/articles/gilead-retained-at-neutral-analyst-blog-2013-06-25", "https://www.nasdaq.com/articles/evenly-poised-on-regeneron-analyst-blog-2013-06-25", "https://www.nasdaq.com/articles/eu-nod-for-medivation-astellas-xtandi-analyst-blog-2013-06-27", "https://www.nasdaq.com/articles/pluristem-cha-collaborate-in-south-korea-analyst-blog-2013-06-27", "https://www.nasdaq.com/articles/us-exclusivity-for-raptors-procysbi-analyst-blog-2013-06-26", "https://www.nasdaq.com/articles/cytokinetics-astellas-collaborate-analyst-blog-2013-06-26", "https://www.nasdaq.com/articles/data-from-hyperions-ucd-drugs-analyst-blog-2013-06-24", "https://www.nasdaq.com/articles/new-data-on-novo-nordisks-tresiba-analyst-blog-2013-06-24", "https://www.nasdaq.com/articles/theravances-vibativ-expanded-in-the-us-analyst-blog-2013-06-24", "https://www.nasdaq.com/articles/positive-data-on-infinitys-oncology-candidate-analyst-blog-2013-06-25", "https://www.nasdaq.com/articles/sgen-takeda-report-data-on-adcetris-analyst-blog-2013-06-21", "https://www.nasdaq.com/articles/draft-guidance-from-nice-for-psividas-iluvien-analyst-blog-2013-06-21", "https://www.nasdaq.com/articles/raptor-pharmas-procysbi-launched-in-the-us-analyst-blog-2013-06-21", "https://www.nasdaq.com/articles/takeda-launches-diabetes-drugs-analyst-blog-2013-06-21", "https://www.nasdaq.com/articles/ruconest-under-fda-review-analyst-blog-2013-06-20", "https://www.nasdaq.com/articles/nektars-pain-drug-impresses-analyst-blog-2013-06-20", "https://www.nasdaq.com/articles/novo-nordisk-patent-found-invalid-analyst-blog-2013-06-19", "https://www.nasdaq.com/articles/endo-health-to-shell-out-%2454.5-million-analyst-blog-2013-06-24", "https://www.nasdaq.com/articles/sgen-takeda-report-data-on-adcetris-analyst-blog-2013-06-21", "https://www.nasdaq.com/articles/draft-guidance-from-nice-for-psividas-iluvien-analyst-blog-2013-06-21", "https://www.nasdaq.com/articles/viropharma-up-on-takeover-rumors-analyst-blog-2013-06-18", "https://www.nasdaq.com/articles/data-on-astex-candidate-analyst-blog-2013-06-18", "https://www.nasdaq.com/articles/positive-data-on-incytes-jakafi-analyst-blog-2013-06-18", "https://www.nasdaq.com/articles/ariads-iclusig-in-gist-phase-ii-study-analyst-blog-2013-06-18", "https://www.nasdaq.com/articles/valeant-raising-funds-analyst-blog-2013-06-19", "https://www.nasdaq.com/articles/mannkind-completes-afrezza-studies-analyst-blog-2013-06-18", "https://www.nasdaq.com/articles/good-news-for-celgenes-revlimid-analyst-blog-2013-06-17", "https://www.nasdaq.com/articles/us-launch-of-forests-namenda-xr-analyst-blog-2013-06-17", "https://www.nasdaq.com/articles/elan-explores-sale-options-analyst-blog-2013-06-17", "https://www.nasdaq.com/articles/xoma-commences-gevokizumab-study-analyst-blog-2013-06-17", "https://www.nasdaq.com/articles/positive-data-on-incyte-llys-baricitinib-analyst-blog-2013-06-14", "https://www.nasdaq.com/articles/encouraging-data-from-bristol-myers-analyst-blog-2013-06-13", "https://www.nasdaq.com/articles/acquisitions-add-jazz-pharmas-diversity-2013-06-18", "https://www.nasdaq.com/articles/celg-presents-positive-long-term-data-analyst-blog-2013-06-13", "https://www.nasdaq.com/articles/incytes-jakafi-label-updated-analyst-blog-2013-06-13", "https://www.nasdaq.com/articles/apricus-vitaros-approved-in-europe-analyst-blog-2013-06-11", "https://www.nasdaq.com/articles/encouraging-data-on-alexions-soliris-analyst-blog-2013-06-10", "https://www.nasdaq.com/articles/royalty-offer-remains-unattractive-to-elan-analyst-blog-2013-06-10", "https://www.nasdaq.com/articles/hyperion-acquires-buphenyl-rights-analyst-blog-2013-06-10", "https://www.nasdaq.com/articles/update-on-gentiums-defibrotide-analyst-blog-2013-06-10", "https://www.nasdaq.com/articles/fda-panel-meeting-for-salix-drug-analyst-blog-2013-06-13", "https://www.nasdaq.com/articles/celg-presents-positive-long-term-data-analyst-blog-2013-06-13", "https://www.nasdaq.com/articles/incytes-jakafi-label-updated-analyst-blog-2013-06-13", "https://www.nasdaq.com/articles/apricus-vitaros-approved-in-europe-analyst-blog-2013-06-11", "https://www.nasdaq.com/articles/encouraging-data-on-alexions-soliris-analyst-blog-2013-06-10", "https://www.nasdaq.com/articles/royalty-offer-remains-unattractive-to-elan-analyst-blog-2013-06-10", "https://www.nasdaq.com/articles/endo-to-trim-workforce-analyst-blog-2013-06-06", "https://www.nasdaq.com/articles/nektar-presents-data-on-oncology-candidates-analyst-blog-2013-06-05", "https://www.nasdaq.com/articles/astrazeneca-resolves-nexium-issue-analyst-blog-2013-06-10", "https://www.nasdaq.com/articles/label-expansion-sought-for-amag-tkpyys-rienso-analyst-blog-2013-06-10", "https://www.nasdaq.com/articles/pfizer-in-%24635-million-deal-analyst-blog-2013-06-07", "https://www.nasdaq.com/articles/biolinerx-enrolls-first-patient-in-study-analyst-blog-2013-06-07", "https://www.nasdaq.com/articles/positive-data-on-bayer-regns-eye-drug-analyst-blog-2013-06-07", "https://www.nasdaq.com/articles/avanir-to-expedite-avp-786-development-analyst-blog-2013-06-06", "https://www.nasdaq.com/articles/endo-to-trim-workforce-analyst-blog-2013-06-06", "https://www.nasdaq.com/articles/nektar-presents-data-on-oncology-candidates-analyst-blog-2013-06-05", "https://www.nasdaq.com/articles/astellas-launch-plans-for-acofide-analyst-blog-2013-06-05", "https://www.nasdaq.com/articles/glaxo-renaissance-ink-deal-analyst-blog-2013-06-04", "https://www.nasdaq.com/articles/glaxo-reports-votrient-data-analyst-blog-2013-06-03", "https://www.nasdaq.com/articles/idenix-pharma-initiates-phase-ii-study-analyst-blog-2013-05-31", "https://www.nasdaq.com/articles/patent-challenge-from-perrigo-analyst-blog-2013-05-31", "https://www.nasdaq.com/articles/array-onty-to-co-develop-arry-380-analyst-blog-2013-05-31", "https://www.nasdaq.com/articles/postive-interim-data-on-paciras-exparel-analyst-blog-2013-05-31", "https://www.nasdaq.com/articles/novo-nordisk-seeks-ideglira-approval-analyst-blog-2013-06-03", "https://www.nasdaq.com/articles/cash-and-tysabri-update-from-elan-analyst-blog-2013-05-30", "https://www.nasdaq.com/articles/bayer-a-step-closer-to-conceptus-buy-analyst-blog-2013-05-30", "https://www.nasdaq.com/articles/two-top-endo-executives-depart-analyst-blog-2013-05-30", "https://www.nasdaq.com/articles/omeros-files-cta-for-ahus-candidate-analyst-blog-2013-05-29", "https://www.nasdaq.com/articles/positive-data-on-salixs-budesonide-foam-analyst-blog-2013-05-29", "https://www.nasdaq.com/articles/fda-accepts-omeros-ind-for-oms824-analyst-blog-2013-05-28", "https://www.nasdaq.com/articles/jjs-promising-pharma-pipeline-analyst-blog-2013-05-28", "https://www.nasdaq.com/articles/glaxos-oncology-portfolio-gets-a-boost-analyst-blog-2013-05-30", "https://www.nasdaq.com/articles/promising-data-on-oncys-reolysin-analyst-blog-2013-05-24", "https://www.nasdaq.com/articles/elan-rejects-royalty-offer-again-analyst-blog-2013-05-24", "https://www.nasdaq.com/articles/ironwood-pharma-prices-stock-offering-analyst-blog-2013-05-23", "https://www.nasdaq.com/articles/pfizer-halts-inotuzumab-study-analyst-blog-2013-05-23", "https://www.nasdaq.com/articles/nps-pharma-prices-offering-analyst-blog-2013-05-23", "https://www.nasdaq.com/articles/repros-to-conduct-phase-iib-trial-analyst-blog-2013-05-23", "https://www.nasdaq.com/articles/abbvie-extends-galapagos-deal-analyst-blog-2013-05-22", "https://www.nasdaq.com/articles/eu-approval-for-bayer-jnjs-xarelto-analyst-blog-2013-05-28", "https://www.nasdaq.com/articles/promising-data-on-oncys-reolysin-analyst-blog-2013-05-24", "https://www.nasdaq.com/articles/sanofi-regns-dupilumab-data-published-analyst-blog-2013-05-22", "https://www.nasdaq.com/articles/generic-launches-at-mylan-continue-analyst-blog-2013-05-22", "https://www.nasdaq.com/articles/additional-patent-for-acordas-ampyra-analyst-blog-2013-05-22", "https://www.nasdaq.com/articles/elan-provides-strategic-update-analyst-blog-2013-05-21", "https://www.nasdaq.com/articles/fda-accepts-actavis-nda-analyst-blog-2013-05-20", "https://www.nasdaq.com/articles/nektar-posts-wider-loss-maintains-view-analyst-blog-2013-05-15", "https://www.nasdaq.com/articles/xenoport-resumes-horizant-supply-analyst-blog-2013-05-22", "https://www.nasdaq.com/articles/dr.-reddys-earnings-increase-y-y-analyst-blog-2013-05-15", "https://www.nasdaq.com/articles/synergy-pharma-posts-wider-loss-analyst-blog-2013-05-15", "https://www.nasdaq.com/articles/good-news-for-novartis-ilaris-analyst-blog-2013-05-15", "https://www.nasdaq.com/articles/forest-trevena-ink-deal-analyst-blog-2013-05-14", "https://www.nasdaq.com/articles/jazz-pharma-posts-higher-y-y-earnings-analyst-blog-2013-05-14", "https://www.nasdaq.com/articles/lilly-scraps-oncology-candidate-analyst-blog-2013-05-13", "https://www.nasdaq.com/articles/narrower-than-expected-loss-at-mannkind-analyst-blog-2013-05-13", "https://www.nasdaq.com/articles/merck-kgaa-posts-higher-y-y-earnings-analyst-blog-2013-05-15", "https://www.nasdaq.com/articles/big-move-expected-jazz-pharma-2013-03-27", "https://www.nasdaq.com/articles/jazz-beats-eps-misses-sales-analyst-blog-2013-03-05", "https://www.nasdaq.com/articles/after-hours-earnings-report-february-26-2013-pcln-vno-eix-rrc-wft-vrsk-avgo-awk-erie-jazz", "https://www.nasdaq.com/articles/jazz-provides-portfolio-update-analyst-blog-2013-01-14", "https://www.nasdaq.com/articles/jazz-initiates-erwinaze-trial-analyst-blog-2012-12-05", "https://www.nasdaq.com/articles/jazz-pharma-3q-earnings-in-line-analyst-blog-2012-11-09", "https://www.nasdaq.com/articles/after-hours-earnings-report-november-8-2012-dis-psa-jwn-nvda-mchp-cfn-enr-flt-igt-gxp-jazz", "https://www.nasdaq.com/articles/teva-alexza-sign-deal-for-adasuve-analyst-blog-2013-05-13", "https://www.nasdaq.com/articles/markets-consolidate-dow-muscles-higher-2012-09-18", "https://www.nasdaq.com/articles/jazz-to-sell-womens-health-suite-analyst-blog-2012-09-13", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-plc-enters-oversold-territory-tale-of-the-tape-2012-09-04", "https://www.nasdaq.com/articles/after-hours-earnings-report-august-7-2012-dis-esrx-ete-xl-rgp-wr-wri-bwc-cree-jazz-urs-anv", "https://www.nasdaq.com/articles/new-powershares-small-cap-relative-strength-etf-2012-07-23", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-aggressive-growth-2012-06-18", "https://www.nasdaq.com/articles/jazz-closes-eusa-acquisition-analyst-blog-2012-06-14", "https://www.nasdaq.com/articles/jazz-divests-womens-health-suite-analyst-blog-2012-10-22", "https://www.nasdaq.com/articles/10-biotech-stocks-trading-deep-discounts-analyst-target-prices-2011-10-31", "https://www.nasdaq.com/articles/stocks-rebound-trade-higher-amid-mixed-slate-earnings-china-data-weighs-2011-10-18", "https://www.nasdaq.com/articles/mid-day-update-stocks-shift-higher-after-mixed-start-china-earnings-weigh-2011-10-18", "https://www.nasdaq.com/articles/investing-101-rallying-healthcare-stocks-being-snapped-smart-money-2011-08-31", "https://www.nasdaq.com/articles/market-got-you-down-here-are-ten-good-reasons-remain-optimistic-2011-08-11", "https://www.nasdaq.com/articles/crisis-creates-rare-opportunity-these-4-stocks-2011-08-02", "https://www.nasdaq.com/articles/july-14th-top-performing-small-cap-stocks-ufpi-bth-utek-gluu-jazz-2011-07-15", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-plc-enters-oversold-territory-tale-of-the-tape-2012-04-19", "https://www.nasdaq.com/articles/5-rallying-biotech-stocks-being-snapped-insiders-2011-02-24", "https://www.nasdaq.com/articles/quarters-top-performing-growth-stocks-2010-12-13", "https://www.nasdaq.com/articles/momentum-plays-14-stocks-reaching-new-highs-institutional-buying-2010-11-18", "https://www.nasdaq.com/articles/trader-sticks-jazz-pharma-2010-11-09", "https://www.nasdaq.com/articles/us-indexes-trade-modestly-higher-extending-fridays-gains-deals-top-market-news-2010-10-11", "https://www.nasdaq.com/articles/mid-day-update-stocks-modestly-higher-investors-look-ahead-tomorrows-fed-minutes-2010-10", "https://www.nasdaq.com/articles/bulls-target-jazz-fda-ruling-2010-10-05", "https://www.nasdaq.com/articles/could-be-perfect-biotech-portfolio-2011-07-11", "https://www.nasdaq.com/articles/tuesday-winners-kornferry-international-jazz-pharma-and-carmike-cinemas-2010-06-15"], "Content": []}